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Abstract
Kaposi's Sarcoma (KS) is a malignancy caused by infection with Kaposi's Sarcoma-associated 
Herpesvirus [KSHV; also known as Human Herpesvirus 8 (HHV8)] in which tumor cells show a 
characteristic 'spindle-like' morphology. The transcription factor RTA (Replication and 
Transcription Activator) is the viral protein responsible for reactivating KSHV from its latent 
state. Production of RTA in latently infected cells causes a number of viral proteins to be 
produced and leads to a cascade of gene expression changes in both viral and host genes. 
Previous work in our lab showed that RTA was capable of reprogramming cells in vitro to 
display a spindle-like morphology. In this study we aimed to identify the host gene expression 
changes caused directly by RTA which could be responsible for that reprogramming. To that 
end, Madin-Darby Canine Kidney cells (MDCK cells) were chosen as a model for KSHV-naive 
mammalian cells. Differences in host gene expression levels in a culture of MDCK cells 
transfected with a plasmid coding for expression of RTA compared to MDCK cells transfected 
with a similar plasmid lacking the RTA gene were measured by whole transcriptome sequencing 
(RNA-Seq). Cells containing the RTA-coding plasmid adopted a spindle-like morphology and 
showed at least a two-fold change in expression level in approximately 180 genes. Those 180 
genes were then screened for known associations to signaling pathways in order to determine 
which might be involved with the morphological changes observed and/or biological 
significance. The expression levels of the 10 genes identified by that screening were then 
verified by quantitative real time PCR (qPCR). Of those 10 genes, eight were identified as 
potentially associated with the morphological changes, including three genes associated with 
extra cellular matrix (ECM) destruction (MMP9, CTSD, and CTSS) that were down-regulated; 
two genes associated with blocking ECM destruction (TIMP1 and TIMP2) that were up- 
regulated; two ECM component genes (LAMC2 and COL1A2) that were upregulated; and one 
gene associated with blocking cell-cell and cell-ECM adhesion (MUC1) that was downregulated. 
The remaining two genes (MAP2K1 and podoplanin) were identified as potentially biologically 
significant, but not directly involved in regulating morphology. MAP2K1 is associated with 
epithelial dedifferentiation and was down-regulated; and the lymphatic endothelial specific 
marker podoplanin (PDPN) was up-regulated. Taken together, the differences in morphology
v
and gene expression between RTA-producing cells and controls suggest a possible role for RTA 
in the formation of the spindle cells that characterize Kaposi's sarcoma.
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Chapter 1. General Introduction
Kaposi's sarcoma (KS) is a malignant neoplasm first described in 1872 by Dr. Moritz Kaposi. KS is 
characterized as a spindle-cell tumor with variable clinical features ranging from minimal 
mucocutaneous disease to extensive organ involvement. KS can be primarily categorized into 4 
types: Classic, Endemic (African), iatrogenically immunocompromised, and AIDS-related. Classic 
KS was a rare condition affecting elderly men of Mediterranean descent. It presented as highly 
vascular lesions on the toes and/or soles of the feet. The lesions progressed very slowly, and 
were rarely fatal. In the 1960's endemic KS was discovered in central Africa [Hutt and Burkitt, 
1965]. The African variant was much more malignant, and occurred in much younger people. 
Most African patients were males under 30 years old. While the disease was common in certain 
hotspots in Africa, it was extremely rare in the North America until the early 1980s [Beral et al., 
1990]. In 1981 groups of young homosexual men were diagnosed with a highly aggressive form 
of KS in New York and California. This extremely unusual grouping, along with cases of 
Pneumocystis carinii pneumonia infection in other groups of young homosexual men that had 
previously been healthy, signaled the start of the AIDS epidemic [Curran and Jaffe, 2011]. KS 
incidence in the United States went from 1-2 per million people per year before the AIDS 
epidemic, to 47 cases per million people per year afterward [Eltom et al., 2002]. Before 
effective treatments for HIV were invented, people with AIDS had roughly a 50% chance of 
developing KS. It became so common among AIDS patients that KS was categorized as an 'AIDS- 
defining illness', and developing KS was often how people discovered that they had AIDS. In 
addition to AIDS patients, there was one more group that had a massively higher risk of 
developing KS: organ transplant recipients taking immunosuppressive drugs to prevent 
rejection had a 1 in 200 chance of developing KS [Farge, 1993].
The fact that KS risk was increased not just in patients with HIV, but in other 
immunocompromised groups as well, suggested that it was not HIV itself causing the tumors, 
but rather the immune suppression from HIV was somehow allowing the tumors to develop. In 
1994 a team at Columbia University discovered the virus that was causing KS , and named it 
Kaposi's Sarcoma-associated Herpesvirus [KSHV; also known as Human Herpesvirus 8 (HHV8)] 
[Chang et al., 1994]. KSHV is a gammaherpesvirus, related to another well-known tumor virus,
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Epstein-Barr virus. In addition to KS, KSHV also causes primary effusion lymphoma (PEL, a 
cancer of the lymphocytes) also called body cavity-based lymphoma (BCBL) and some forms of 
severe lymph node enlargement, called Castleman's disease [Cesarman et al., 1995]. PEL is a 
highly aggressive B-cell tumor that (like KS) appears in severely immunocompromised 
individuals infected with KSHV. Despite sharing a common cause, the pathologies, 
morphologies, and prognoses of the two malignancies are very different. KS tumors are made 
up of characteristic 'spindle cells' which have an endothelial morphology, as well as immature 
blood vessels, and inflammatory infiltrate [Ensoli and Sturzl, 1998]. KS forms multiple lesions on 
the skin and oral mucosa, and in late stages can involve the lymph nodes and visceral organs as 
well. Conversely, PEL does not form solid tumors at all. Instead, it takes the form of round 
lymphoblastic cells rapidly growing in suspension. While patients diagnosed with classic KS can 
live for years and will typically die of unrelated causes, PEL patients often die within 6-months 
of diagnosis, and rarely survive more than a year [Patel and Xiao, 2013].
Another major difference between PEL and KS involves the life cycle of the virus itself. PEL cells 
all contain intact copies of the viral genome, and can be successfully cultured in the lab to 
maintain a continuous cell line. In KS tissue, many of the spindle cells do not contain KSHV 
genome in situ. The proportion of spindle cells containing the KSHV genome increases as the 
tumor progresses. As few as 10% of spindle cells in early stage tumors can be detected with 
KSHV; but in the later stages that number can be as high as 90% or more [Cancian et al., 2013]. 
Numerous attempts have been made to generate stable KSHV-infected cell lines from KS 
spindle cells, but all have failed [Grundhoff and Ganem, 2004]. It was found that the spindle 
cells could not grow in culture without the addition of exogenous growth factors, and that even 
with those growth factors the spindle cells rapidly lost the KSHV genome, showing that the 
infection was not stable (at least in vitro) [Grundhoff and Ganem, 2004].
Finally, as far as morphology and cell surface marker proteins are concerned, PEL cells resemble 
lymphatic B-cells; while KS spindle cells morphologically resemble endothelial cells and show 
surface markers associated with both blood and lymphatic endothelium [Cancian et al., 2013; 
Carroll et al., 2004; Gessain and Duprez, 2005; Pyakurel et al., 2006]. The vast differences 
between KS and PEL begged the question of how a single virus could cause both diseases. The
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initial idea was that the two malignancies resulted from KSHV infection of different cell types, 
with the B-cell-like PEL originating from transformed B-cells, and the endothelial-like KS 
originating from endothelial cells [Staskus et al., 1999]. The hypothesis that PEL originated from 
B-cells was consistent with the known ability of KSHV to establish latent infection of B-cells in 
vivo, and the fact that PEL cells closely resemble B-cells. None of the evidence suggested a 
different origin.
The origin of KS was less clear. First, KS spindle cells did not resemble any particular cell type. 
Morphologically they were similar to endothelial cells, but molecularly they displayed an 
indistinct phenotype; they expressed genes specific to blood endothelial cells, but also genes 
specific to lymphatic endothelial cells. In other words, it seemed clear that they originated from 
endothelial cells of some kind, but whether they came from lymphatic or blood endothelial cells 
remained unknown. This indistinct phenotype was later found to result from the virus 
reprogramming host cells. When the virus infected blood endothelial cells, it would push them 
to a more lymphatic-like gene expression profile [Carroll et al., 2004]. And when it infected 
lymphatic endothelial cells, it would push them to a more blood-like gene expression profile 
[Wang et al., 2004]. Regardless of which cell type they started out as, the reprogrammed cells 
showed a gene expression pattern that was roughly 70% lymphatic endothelial and 30% blood 
endothelial. The fact that KSHV reprogramed host cell gene expression patterns meant that 
those patterns could not be used to infer which type of cells gave rise to KS spindle cells.
After it was discovered that KSHV had the ability to reprogram surface marker protein patterns, 
the next logical steps were to determine if the virus was able to reprogram host cell 
morphology as well and, if so, what conditions were needed to trigger it, and by what 
mechanism was it accomplished. The vast majority of KS cases are the result of KSHV-infected 
individuals becoming immunocompromised. Immunosuppression triggers the viral genomes in 
latently infected cells to begin producing the viral protein RTA (Replication and Transcription 
Activator) [Greene et al., 2007; Guito and Lukac, 2012]. RTA is a transcriptional transactivator 
that stimulates the production of a cascade of viral proteins that initiate lytic replication. 
Somehow either RTA, or the proteins in the cascade it activates, cause KS to form. If
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morphological reprogramming is part of KS formation, then RTA is either directly or indirectly 
(through the other genes it activates) responsible for that reprogramming.
Previous work in our lab tested whether lytic reactivation of KSHV was capable of 
reprogramming cell morphology in vitro (J. Chen, unpublished work, 2013). The PEL-derived 
BCBL-1 (Body Cavity Based Lymphoma 1) cell line was selected as a model because it was 
latently infected with KSHV. BCBL-1 cells were treated with phorbol ester (12-O-tetradecanoyl 
phorbol-13 acetate [TPA], Sigma, MO) to induce RTA expression and initiate lytic replication. At 
that time some of the cells were indeed morphologically reprogrammed to become spindle 
shaped and began adhering to each other and to the culture flask. Those reprogrammed cells 
(dubbed BCBL-E cells) were isolated and cultured. Whole transcriptome sequencing (RNA-Seq) 
comparing BCBL-E and BCBL-1 cells showed expression of over 500 genes had been either up- 
or down-regulated by at least two-fold; but gave no way to differentiate the effects caused 
directly by RTA from effects caused by the cascade of other viral proteins produced during lytic 
reactivation.
Differentiating those effects required the creation of a new set of KSHV-naive cell lines 
modified to express RTA, but lacking all other viral components. To this aim, a plasmid vector 
coding for expression of RTA was transfected into a mammalian cell line that was not infected 
with KSHV. In this way RTA would be expressed in that cell line and would be capable of 
interacting with the host genome, but no other viral genes would be present. Therefore, if 
morphological reprogramming did occur in those cells, then it would have to have been caused 
directly by RTA. MDCK (Madin-Darby Canine Kidney) cells were chosen because they were not 
infected with KSHV, and unlike many human cell lines they were permissive of expressing KSHV 
proteins. Two types of MDCK cell lines were created by transfection with one of two plasmids. 
The treatment cells were named RTA+ and received a plasmid coding for constitutive 
expression of viral RTA. The control cells were named RTA- and received a similar plasmid that 
lacked the RTA gene. Like the BCBL-E cells, the RTA+ cells took on a spindle-like shape. RNA-Seq 
comparison between RTA+ and RTA- cells identified 180 genes for which expression was up- or 
down-regulated at least two-fold (J. Chen, unpublished work, 2014). With KSHV's ability to 
reprogram host cell morphology established, and immunosuppression-induced RTA production
4
identified as the trigger, the goal of this study was to identify the possible mechanisms RTA was
using to effect that reprogramming.
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Chapter 2. KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS REPLICATION AND TRANSCRIPTION 
ACTIVATOR REGULATES EXTRACELLULAR MATRIX SIGNAL PATHWAY
2.1. Abstract
Kaposi's sarcoma (KS) is a malignancy characterized by spindle-shaped tumor cells believed to 
be of endothelial origin. KS arises when individuals infected with Kaposi's sarcoma-associated 
herpesvirus [KSHV; also known as human herpesvirus 8 (HHV8)] become severely 
immunocompromised. Immunosuppression triggers production of KSHV's lytic switch protein 
RTA (Replication and Transcription Activator) in latently infected cells. RTA initiates lytic 
replication by setting off a cascade of both host and viral gene expression changes. Previous 
work in this lab showed that RTA was capable of reprogramming host cells to display a spindle­
shaped morphology in both KSHV-infected and KSHV-naive cell cultures in vitro. This study 
analyzed the gene expression changes in KSHV-naive cells caused by RTA to identify possible 
mechanisms driving the morphological reprogramming. The analysis identified 8 genes involved 
in extra cellular matrix (ECM) remodeling, 1 gene involved in blocking cell-cell and cell-ECM 
adhesion, and 1 gene involved in epithelial/endothelial differentiation as the most likely drivers 
of the reprogramming.
2.2. Introduction
Kaposi's sarcoma-associated herpesvirus (KSHV; also called human herpesvirus 8 or HHV8) is a 
gammaherpesvirus which infects B-lymphocytes and endothelial cells [Dittmer and Damania, 
2013]. KSHV can remain in its latent phase for decades in healthy individuals before 
immunosuppression triggers the production of the virus's lytic switch protein RTA (Replication 
and Transcription Activator) [Greene et al., 2007; Guito and Lukac, 2012]. RTA induced lytic 
reactivation of KSHV in severely immunosuppressed individuals directly causes nearly all cases 
of Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL) [Moore and Chang, 2003]. Prior 
to widespread use of effective anti-retroviral therapy in the developed world, KS was found in 
approximately half of all AIDS patients [Moore and Chang, 2003], and it is currently the sixth 
most common cancer diagnosed in Africa [Abratt and Vorobiof, 2003].
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KS tumors are highly vascular lesions made up of spindle-shaped cells, immature blood vessels, 
and inflammatory infiltrate [Ensoli and Sturzl, 1998]. Spindle cells display an endothelial-like 
morphology, and a pattern of surface marker proteins that is intermediate between blood and 
lymphatic endothelium [Pyakurel et al., 2006]. Reprogramming of surface marker patterns is 
not uncommon during oncogenesis, and KS is no exception. When either blood or lymphatic 
endothelial cells are infected with KSHV in vitro, the same intermediate surface marker pattern 
is induced [Carroll et al., 2004; Wang et al., 2004]. Additionally, spindle cells from biopsies often 
contain fragments of KSHV DNA as well as complete virions, but rapidly lose both when 
cultured, implying that the infection is not stable [Orenstein et al., 1997]. In contrast to KS, the 
B-lymphocyte-derived PEL cells do not form solid tumors, and are capable of maintaining a 
stable latent KSHV infection when cultured [Patel and Xiao, 2013]. Both morphologically and in 
regard to surface markers, PEL cells resemble B-cells growing rapidly in suspension. And while 
the progression of classic KS is so slow that patients often die of unrelated causes, patients 
diagnosed with PEL rarely survive a year. The most commonly accepted hypothesis for how a 
single virus can cause these two starkly different malignancies is that KS results from 
transformed endothelial cells, and PEL results from transformed B-cells [Staskus et al., 1999]. 
The many similarities between B-lymphocytes and PEL cells strongly support a B-cell origin. The 
origin of KS was less clear; given that the surface marker patterns in spindle cells were being 
reprogrammed by KSHV, the only evidence that spindle cells originated from endothelial cells 
was their endothelial-like morphology. However, previous work in our lab showed that RTA- 
induced lytic reactivation of KSHV was capable of morphologically reprogramming PEL-derived 
BCBL-1 (Body Cavity Based Lymphoma 1) cells in vitro to display a spindle-like morphology (J. 
Chen, unpublished work, 2013); indicating that (like surface marker patterns) morphology is not 
a reliable indicator of the cellular origin of KS spindle cells.
The finding that RTA-induced lytic reactivation of KSHV is capable of reprogramming host cell 
morphology opened the possibility that KS may share the same B-cell origin as PEL, but it came 
with two key limitations. First, that finding did not indicate whether the cause of the 
reprogramming was RTA itself or one of the many viral proteins produced in response to RTA. 
And second, it did not provide any insight into the mechanisms by which the reprogramming
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was accomplished. The first point was addressed when further work in our lab showed that 
KSHV-naive MDCK (Madin-Darby Canine Kidney) cells transfected with a plasmid vector coding 
for RTA expression adopted a spindle-shaped morphology, indicating that the reprogramming 
was being caused by RTA directly (J. Chen, unpublished work, 2014). This study aimed to 
address the second point by examining differences in gene expression between MDCK cells 
transfected with the RTA coding plasmid (RTA+ cells) and MDCK cells transfected with a similar 
plasmid lacking the RTA coding region (RTA- cells) in order to identify signaling pathways 
altered by RTA that could be responsible for the observed morphological reprogramming. A 
number of factors have been implicated in the control of cell morphology. The extracellular 
matrix (ECM) is one example. Changes in the ECM can result in dramatic changes to cell shape 
[Lukashev and Werb, 1998; Watt, 1986]. Individual ECM components such as collagen and 
laminin can modulate cell shape [Elliott et al., 2003; Ingber et al., 1995; Watt, 1986], as can 
large scale remodeling of the ECM [Gospodarowicz et al., 1978; Guilak et al., 2009; Lin and 
Bissell, 1993; Lukashev and Werb, 1998]. Other factors can also influence cell shape such as 
actin [Pollard and Cooper, 2009], neurotrophins [Bibel, 2000], and cell surface mechanics such 
as mechanical stress and cell-cell/cell-ECM adhesion [Ingber et al., 1995; Lecuit and Lenne, 
2007]. We hypothesized that genes associated with one or more of these pathways would be 
altered by RTA.
2.3. Methods
2.3.1. Formal Virus Name
Family Herpesviridae, Subfamily Gammaherpesvirinae, Genus Rhadinovirus, Species Human 
herpesvirus 8.
2.3.2. Confirmation of Cell Line Identity
Cultures of the RTA+ and RTA- MDCK cell lines described in the introduction were utilized in this 
study. Presence or absence of the RTA gene in each cell line was verified in a three step 
process. First, DNeasy Blood and Tissue Kits (Qiagen, Hilden, Germany) were used to extract the
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genomic DNA from BCBL-1 cells (BG, Figure 1). RNeasy Mini Kits (Qiagen, Hilden, Germany) 
were used to extract total RNAs from BCBL-1 cells and the RTA+ and RTA- cell lines. Total RNAs 
were reverse transcribed into cDNA from BCBL-1 cells (BC, Figure 1) and from the RTA+ and 
RTA- cells (RTA- and RTA+, respectively, Figure 1). Second, PCR was used to amplify the RTA 
gene and transcript from the cDNA extracted from the RTA+ and RTA- cells, as well as genomic 
DNA or cDNA from three control groups. The first two controls were gDNA and cDNA from a cell 
line (BCBL-1) infected with KSHV. The third control was the plasmid DNA used to create the 
RTA+ cells. The primers used in the PCR were capable of amplifying both the full length genomic 
loci of the RTA gene (~1350 bp) and the shorter cDNA version of the RTA transcript (~400 bp) 
that was used to construct the RTA+ plasmid. Third, an agarose gel electrophoresis was 
performed on the five PCR products to determine which versions of RTA (if any) were present in 
each sample. Presence of only the genomic-length version of RTA would indicate the presence 
of KSHV genome; presence of only the shorter cDNA-length version of RTA would indicate that 
the sample either contained RTA transcript (RTA+ in Figure 1), or contained the RTA+ plasmid; 
presence of both versions of RTA in sample would indicate that the cell line contained both 
KSHV genome and RTA transcript from active infection; and absence of both versions would 
indicate a lack of either RTA gene or RTA transcript.
2.3.3. Genes Eliminated for Technical Reasons
Prior to the beginning of this study whole-transcriptome sequencing (RNA-Seq) had generated a 
list of 180 genes whose expression level was at least 2-fold different in RTA+ cells as compared 
to RTA- cells. Before investigating potential biological significance, this study began by 
screening each gene to ensure that it met two technical criteria. The first criterion was that the 
gene must be expressed at some level in both the RTA+ and RTA- cells. Genes showing zero 
expression in either cell line were eliminated because fold-change cannot be computed if one 
of the values is zero, and the fact that RTA is a transcriptional transactivator (and therefore 
unlikely to turn a gene entirely on or off). The second criterion was that the gene must support 
cDNA specific primers. Primer sets were designed for each of the remaining genes using the
10
Primer-Blast tool from NCBI (http://www.ncbi.nlm.nih.gov/tools/primer-blast) with the 
condition that either the forward or reverse primer must span an exon-exon gap to ensure that 
genomic DNA would not be amplified (Table 1).
Table 1: Forward and reverse primer sequences used for qPCR. Note: Both the order o f genes listed in this 
table and their placement in either the right or left column are arbitrary and do not signify any 
meaningful differences between either the genes or their primer sequences.
Gene Primer Sequence
CCL2- F TCACCCAGCCAGATGCAATTA
CCL2 - R TCTTTGGGACACTTGCTGCT
CTSS - F AAATACCAGGGTTCTTGTGGTG
CTSS - R AG CAATCTACCAAGTTCTGTGC
SNAI2 - F GGACACGCACACAGTGATTATT
SNAI2 - R CCATTGGGTAGTGGGGAGTG
GUCA2A - F CCATGAACACCTTCCTGCTC
GUCA2A - R AGAAGTCTCCGTCCTGCAC
PRKDC - F CATTGCACCCGGAGATGAAC
PRKDC - R TGCTCACACAGTCCTCCAAA
CXCL10 - F CCACATGTTGAGATCATTGCCA
CXCL10 - R TCAGACATCTTTTCTCCCCACT
FUT10 - F GAGGTCTCCAATCAGCGACT
FUT10 - R GTAAGCCCTTTTCCTGAAGCC
SEPP1 - F AGGTTTCAGAGCACATTCCTG
SEPP1 - R AGACGGCCACATCTGTCATA
ADRA1B- F GGCATTGTGGTCGGTATGTT
ADRA1B- R TTGAAGTAGCCCAGCCAGAA
CTSC - F CCAGTATGCTCAAGGCTGTG
CTSC - R ACGGAAG CAGTCATTTGGTT
BCL2L2 - F AACCTGGCAGGGCTCCAC
BCL2L2 - R ACTAGAGCCCGTGTGTCTGG
Gene Primer Sequence
SETMAR - F CCCTTCCAGTATACTCCTGACC
SETMAR - R ATGACGGAGACAGGAGCAAG
MGMT - F TGTCCAGAGGAAATGACGGA
MGMT -  R TGAACGAACCTCGCTGGAAA
SLC1A1 - F GACGGGACTGCACTCTATGA
SLC1A1- R CCGTGACACTGATGGTGATG
ZFPM2 - F CCGTGACACTGATGGTGATG
ZFPM2 - R GCTCAGATTTTCAGGCCCAA
CXCR7 - F TTGCTCACGACGGGATCATT
CXCR7 - R GAACGGCCACATTGAGACTTT
CYP4A37 - F CAAACCCAGAGGTGTTCGAC
CYP4A37 - R CTCGTTCATGGCAAAGTGCT
COL1A2 - F TACAGGAGGCAACTGCAAGA
COL1A2 - R CTGGGATACCATCGTCACCA
PDPN- F GAGAAAGATGGCCTGGCAAC
PDPN - R GCTCTTTAGGGCGAGTACCT
PSMB8 - F GGGAGCGTATCTCAGTGTCA
PSMB8 - R CCAGGACCCTTCTTATCCCA
MMP9 - F GTGTTAGGGAGCACGGAGAT
MMP9 - R CCCTTGCCCAGAGTCCATAA
CYP4A38 - F AG CACAGTTCTACTGGCACA
CYP4A38 - R CCCGACCCTTTTGGAACTCT
11
Table 1 continued
Gene
CYP4A11 - F 
CYP4A11 - R
Primer Sequence
GCTGCAGCTGCTACT GAAAT 
CTGGIIIIGGGTCAGATCGC
ARG2 - F 
ARG2 - R
AAGGTCAGTGGGCTAAAACG
AAAGGAAGGAGTCTGTTCAGGA
PLAU - F 
PLAU - R
TGTCTAGCGCATCAAACTGC 
GAGTGACCATTCCCCT CGTA
KRT19 - F 
KRT19 - R
GAACCACGAGGAGGAAATCAG
TCACTCAGGATTTTGGCAAGG
PLAU - F 
PLAU - R
GTCT ACCT GGGTCGGTCAAA 
CGGATCTTCAGCAAG GCAAT
MT1E - F 
MT1E - R
CAAGAAGAGTTGCTGCTCCTG 
GGAACAGGTGTTCT CACACATC
CD47- F 
CD47- R
GGTGTTTGGATGTCT CCTTT CA 
CACTGGGGTGCACTCTGA
SELT - F 
SELT - R
CAAG CTCCTAG CATCTGGCA 
ACCACACAGGCACATCATT C
RPS10 - F 
RPS10 - R
CAGGCGCCAAGATGTTGAT 
CACATT CTTGT CGGCCAGTT
LAMC2 - F 
LAMC2 - R
TGGATTCCGCTGTCT CAACT 
GGCGCTAAGAGAACCTTTGG
RPS15A - F 
RPS15A - R
GAATGTCCTGGCAGATGCTC 
AAATTCGCCAATGTAACCAT GC
MAP2K1 - F 
MAP2K1 - R
GTGGGGAGATCAAGCTCTGT
TGGAGTCTTTCTGGCGACAT
DSG3 - F 
DSG3 - R
GGCCATTGATGAAAACACAGG
GCTGAGACAACCACAGAACG
PODXL - F 
PODXL - R
CGGGGAACAATTCGGATGAC 
AGAGGTT CGTCTGGACAGT G
Gene
ARG2- F 
ARG2- R
Primer Sequence
ACCCCTCACCACTTCATCTG
TGGGAGTTGTGGTACCCATT
LMAN2 - F 
LMAN2 - R
ACTGGT GACCTGT CTGACAAT 
ACACTGGGCT CAATCTT GGT
EDN1- F 
EDN1- R
GTCAACACTCCTGAGCACATT
TGTGGTCTGTTGCCTTTGTG
CSF2- F 
CSF2 - R
GACGTGACTGCTGT GATGAATA 
AAGGGATT CTTGAGGCTGGT
RPL27A - F 
RPL27A - R
CAACATGCCATCCAGACTGAG 
CATT ACCCCGGCCTCCTG
RAB2A - F 
RAB2A- R
CCATGGCGTACGCTTATCTC 
AG CACCAAACTCT ACACCGAT
DAG1- F 
DAG1- R
GAACTCGT CAAGGTGT CAGC 
ATCGGTGTCAAGAGGGAGAC
TIMP1 - F 
TIMP1 - R
CAAATCGT CATCAGGGCCAA 
TGTCGACGAAGCGGATGT
HSPB8 - F 
HSPB8 - R
AAATCCAGCTT CCCGCAGA 
GGGGAAGCTCATTGTTGAAGT
TXNRD1- F 
TXNRD1- R
ACCGAGGAGACGGTTAAACA 
AGGACCCACAAACTGT CCAT
CPNE1 - F 
CPNE1 - R
TCCATTTCCT GTGACCACCT 
CAGTT CGGCCAAG CTCAG
PTGER2- F 
PTGER2- R
TGCT CCTT GCCTTTCACAATTT 
AGGAGGCCTAAAGATGGCAA
RPS24 - F 
RPS24 - R
AGACATGGCCTGTATGAGAAGA 
CCAATCTCCAG CTCACTTCTTT
AP3S2 - F 
AP3S2 - R
ATCTT GGACCTCATCCAGGTTT 
TT CCAATACCATCCCACCCA
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Table 1 continued
Gene
GUSB - F 
GUSB - R
Primer Sequence
ACTACTTCAAGACGCTGATTGC
ACAGATGACGTCCACATACGG
PLA2G7 - F 
PLA2G7- R
GGCGCCCGGAAGTTTAAG
GGATGAACCAGTGTGAGGCA
GSTA4- F 
GSTA4- R
GACTCCAGAAAGCCTGAAAGG 
ACTCCAGCGGCAG CTAAAA
CD97- F 
CD97- R
CCTGGAGAATCCTCAGCCAA 
GCAGGTGGTGCTGTT ATTCC
POLDIP2 - F 
POLDIP2 - R
CTCT CGTCCCGAAACCGA 
CAGGACGACACCTCGGTAG
LGALS9 - F 
LGALS9 - R
ACAG CTGCGATTT CAAG GT G 
GCCTGGAGACTGGAAGCTAA
RBM47 - F 
RBM47 - R
CTCTGAGGGTGGGACACAAG
CGGAGACCTGCCAAACAC
FASTK- F 
FASTK- R
CGCTGCAAGTACAGTCACAA 
AGGAAGTCT GTGCAGTAGCC
SLC35C1 - F 
SLC35C1 - R
CTCACTCACCACCGTCTTCA
AGCCAGAAGCCACCAATGAT
SEPX1 - F 
SEPX1 - R
TTTGAGCCGGGTGTCTATGT
TCTGCATGAATGGTCTCCGT
PLA2G15 - F 
PLA2G15- R
TGGACCCCAGCAAAAGTAGT 
TAGGGCCCG MMCATTTGG
PRKACA - F 
PRKACA- R
AGGGCTACATTCAGGTGACA
GTCCACAGCCTTGTTGTAGC
APP - F 
APP - R
CGGTCCCAGGTT AT GACACA 
TGT CATCCGAGTAG MMGCTC
C3H4orf52 - F 
C3H4orf52 - R
GCCGGAGGAGTACCAGAAAG
TCGAGGTGGTGATAGCCTTC
Gene
SLC35A3 - F 
SLC35A3 - R
Primer Sequence
TTGTACAGTGGCCCTCAGATT
GTAAACCCCAGCAAAACCACT
SNRPB2 - F 
SNRPB2 - R
AAAATGCGTGGCACMMGC 
TGCATTTGGT GTT CCCTGAC
TMEM47 - F 
TMEM47 - R
CAGCAGCGATTGGCAGATT
TGTAGAAGCGCCTTCGAGAT
COX16- F 
COX16- R
GTGCGCGAAAAGCTGACAT 
TCCAACAATCAGCAACAG CA
NACA- F 
NACA- R
CAGTCAATTCAGGCCTCCM M 
AGATTCT GTT CCAGACCCTGT
TBX2 - F 
TBX2 - R
ATGGGCATGGGTCACCTG
TTGGGATTCCCTGAGATGCC
GNA11 - F 
GNA11 - R
ATATGACCAAGTGCTGGTGGA
AGAGGATAACCGAGGAGTTCTG
TIMP2 - F 
TIMP2 - R
TGCACATCACCCTTT GTGAC 
CGCGTGATCTT GCACTCAC
ANXA13- F 
ANXA13- R
TCGT CATAG CCAGTCTT ACT CC 
ATGGCM M CGCTTTGGCA
H19 - F 
H19 - R
ATAGGACATGGTCCGGTGTG
TTCAGGAACGCAAAGGAACG
RHPN2- F 
RHPN2- R
GATGGACCTGAGACAGGCTT
GAAGCGGCTCTCCACAAATC
KRT14 - F 
KRT14- R
GTCCTCCAGAGATGT GACCT 
GAGCAGCCTCAGTT CTTGGT
KDM5C - F 
KDM5C - R
GGTGGCTGGTCTACAGATGA
AGAATACCCTTGACATCCCCAA
FLCN - F 
FLCN - R
CCCGGAAAACTT CAAG CCTT A 
AG CAGAGGGCCGTT ATATT CA
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Table 1 continued
Gene Primer Sequence
EFNB2- F CTGGGTCAGCCAGGCATAAT
EFNB2 - R GTGCTGGAACCTGGATTTGG
NFKBIL1 - F CTGGGATTCTGCTGAAGAGGA
NFKBIL1 - R GGAAGCGTCATCTTCAAACCTC
RPS5-F
RPS5-R
TCACTGGTGAGAACCCCCT
CCTGATTCACACGGCGTAG
RPS19-F CCTTCCTCAAAAAGTCTGGG
RPS19-R GTTCTCATCGTAGGGAGCAAG
RPL8-F
RPL8-R
CCATGAATCCTGTGGAGC
GTAGAGGGTTTGCCGATG
DLA-64-F CCCTGCAGCTCACAGATCCT
DLA-64-R CTGCCAGGTCAGGGTGATCT
DLA-88-F TCTCATGCTGCACGTGATGA
DLA-88-R ATCTTGCATCGCTCAGTCCC
DLA-12-F GGCCGGGTCTCACACCTT
DLA-12-R AGCGCAGGTCCTCGTTCA
HLA-DRB1 - F AGGGACACCCCACCACATT
HLA-DRB1 - R AACTCCTCCCGGTTATGGATG
EGF -  F 
EGF -  R
CCAGAGCCAGGGTCAGTAAA
AGAGCCGGTGCCTCTATTAC
FGFR1OP2 -  F GCAGCACTCCAAGGAATTACA 
FGFR1OP2 -  R CTTGCAACCCTGTTGCTCAT
FOSB -  F TCCAGGCGGAGACAGATCA
FOSB -  R AACTCCAGACGCTCCTTCTC
POFUT1 -  F GCACAGACCACTCCAGAAGTA
POFUT1 -  R AGGCGTTCTT CCAGTCAGA
Gene
RHBDF2- F 
RHBDF2- R
TES - F 
TES - R
FZD6 - F 
FZD6 - R
BRCA1 - F 
BRCA1 - R
MUC1 - F 
MUC1 - R
CLNS1A - F 
CLNS1A - R
CGN - F 
CGN - R
ERBB2 - F 
ERBB2 - R
EBAG9 - F 
EBAG9 - R
TGFB1- F 
TGFB1- R
Primer Sequence
GAAGGACTGCTCGGAGACTT
CTGGCCCAGATCAGACTTGT
GCTGGCTGCGATGAGTTAATA
AGCTAGGATGTTGTCGCAGT
CCCAGGTCAAGAGAACAGGA
TGGAGTTACCCTTCCTTCACT
AGTGGCTTCCATGCGATTG
CTGCAGCAGTTCTGGGAATC
ACTGTTCCACCTCCTCCCA
CTCCCTGTGCTGTAAGCTCT
TCTGTTGCTGAAGAAGAAGACAG
GAACATTGCCTCCAATGCTGA
GAGGAGCTTGGGGAGAAGAT
TCTGGCACAGCTCCTTCTTA
TCATTGCTCACAGCCAAGTG
TTCAGGATCTCTGTGAGGCTT
TATGCAGATCTGGCAGAGGAC
CCCAGGAAGTCCACTCTTCA
ATGTCACTGGAGTCGTGAGG
GGCTGGAACTGAACCCGTTA
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2.3.4. Analysis for Potential Biological Significance
The next step was to determine which of the gene expression changes identified by RNA-Seq 
were potentially biologically significant. This was done in three steps. First, the complete list of 
all genes meeting the previously stated technical requirements was analyzed using both 
GeneAnalytics™ (http://geneanalytics.genecards.org) and Ingenuity Pathway Analysis® 
(http://www.qiagen.com/ingenuity) software in order to identify associated pathways. Next, 
those pathways were screened for biological significance and/or potential association with the 
observed morphological changes using GeneCards™ (http://www.genecards.org/) and the NCBI 
gene information database (http://www.ncbi.nlm.nih.gov/gene). The results of those software 
analyses are presented in appendices A and B. Finally, a literature search was performed for 
each of the remaining genes and pathways in order to identify any additional associations.
2.3.5. qPCR Verification of RNA-Seq Results
The relative expression levels reported by RNA-Seq of genes flagged as potentially biologically 
significant was verified by quantitative real-time PCR (qPCR). To this aim, RNeasy Kits (Qiagen, 
Hilden, Germany) were used to extract total RNA from RTA+ and RTA- cells. The isolated RNA 
was treated with DNase to degrade any genomic DNA present, and then reverse transcribed to 
create cDNA. That cDNA was then used to run a series of qPCR's using a StepOnePlus Real-Time 
PCR System (Life Technologies, Carlsbad, CA). Two to seven runs were conducted for each gene, 
and each run contained two replicates per gene. The difference between the mean Ct value 
(the number of cycles required for a well to cross the threshold of detection) for RTA+ and RTA- 
for each gene was defined as ACt value for that gene. The ACt value for each gene was then 
adjusted by subtracting the ACt value for the housekeeping genes RPS5 and RPS9 to generate 
the AACt value for that gene. The fold change in expression for each gene was calculated as 2(- 
AACt) for each run; with final results for each gene reported as the mean and standard deviation 
of the fold change values for all runs. The results were analyzed using the companion software 
for the StepOnePlus real time PCR system.
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2.4. Results
2.4.1. Confirmation of Cell Line Identity
DNA was extracted from the RTA+ and RTA- cell lines along with DNA from plasmid used to 
create the RTA+ cells and genomic DNA (gDNA) and cDNA samples from KSHV infected BCBL-1 
cells as positive controls. The RTA gene was amplified by PCR with primers capable of targeting 
both the genomic loci of the gene present in the virus itself and the shorter cDNA version of the 
gene used to create the RTA+ plasmid. An agarose gel run on the five PCR products (Fig 1) 
showed that, as expected, RTA- cells lacked either version of the RTA gene; and that RTA+ cells 
contained only the shorter cDNA version.
Fig 1: Plasmid uptake and RTA cDNA presence were verified by PCR and agarose gel 
electrophoresis. The plasmid used to make the RTA+ cell line (Vector), as well as both gDNA (BG) 
and cDNA (BC) from KSHV infected BCBL-1 cell cultures were used as positive controls to show  
the longer gDNA version of the RTA gene as well as the shorter cDNA version. RTA+ does not 
show the gDNA version, which indicates that it is not infected with KSHV; but it does show the 
cDNA version, indicating that it took up the plasmid. RTA- lacks both versions, indicating that it 
neither contains RTA cDNA, nor is it infected with KSHV.
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2.4.2. Gene Selection
Previously completed RNA-Seq had identified a list of 180 genes of which expression was at 
least 2-fold different in RTA+ compared to RTA- cells (Figs 2-5). Of these 180 genes, 74 were 
eliminated because they were present in only one of the cell lines. The design of cDNA-specific 
primers for the remaining 106 genes resulted in the elimination of an additional 9 genes, for 
which primers spanning an exon-exon gap could not be constructed, leaving a total of 97 genes 
to be analyzed for biological significance.
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Fig 2: Comparison of selected RNA-Seq (black bars) and qPCR (striped bars) gene expression fold  
change measurements in RTA+ vs RTA- cell lines. This figure shows all genes that were both 
identified by RNA-Seq as upregulated by at least two-fold, and whose expression was 
subsequently measured by qPCR. Genes lacking a striped bar (ARG2, ERBB2, SEPP1, and TES) 
were shown to be upregulated by RNA-Seq, but subsequent qPCR measurements showed them 
to be downregulated. Note: due to the nature of RNA-Seq, error bars are not used when 
presenting RNA-Seq data.
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Fig 3: Comparison of selected RNA-Seq (black bars) and qPCR (striped bars) gene expression fold  
change measurements in RTA+ vs RTA- cell lines. This figure shows all genes that were both 
identified by RNA-Seq as downregulated by at least two-fold, and whose expression was 
subsequently measured by qPCR. Genes lacking a striped bar (CD97, LGALS9, PLA2G15, RAB2A, 
TGFB1, and TXNRD1) were shown to be downregulated by RNA-Seq, but subsequent qPCR 
measurements showed them to be upregulated. Note: due to the nature of RNA-Seq, error bars 
are not used when presenting RNA-Seq data.
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Fig 4: Selected RNA-Seq gene expression fold change measurements in RTA+ vs RTA- cell lines. 
This figure shows all genes that were identified by RNA-Seq as upregulated by at least two-fold, 
but for which expression was not subsequently measured by qPCR either because suitable 
primer sets could not be designed, or because software analysis identified the genes as unlikely 
to be biologically significant. Note: due to the nature of RNA-Seq, error bars are not used when 
presenting RNA-Seq data.
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Fig 5: Selected RNA-Seq gene expression fold change measurements in RTA+ vs RTA- cell lines. 
This figure shows all genes that were identified by RNA-Seq as downregulated by at least two­
fold, but fo r which expression was not subsequently measured by qPCR either because suitable 
primer sets could not be designed, or because software analysis identified the genes as unlikely 
to be biologically significant. Note: due to the nature of RNA-Seq, error bars are not used when 
presenting RNA-Seq data.
2.4.3. Analysis for Potential Biological Significance
Software analysis using GeneAnalytics™ (http://geneanalytics.genecards.org) and Ingenuity 
Pathway Analysis® (http://www.qiagen.com/ingenuity) software identified all pathways 
associated with one or more of the 97 remaining genes (Appendices A and B). Additionally, IPA 
Biomarker Analysis identified 25 of the 97 genes as being associated with b-cells, epithelial 
cells, or both (Fig 6).
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Fig 6: Results of IPA Biomarker Analysis on expression level differences between RTA+ and RTA- 
cell lines as determined by RNA-Seq. Striped bars represent genes associated with both 
epithelial cells and b-cells; the white bar represents a gene associated with epithelial cells, but 
not associated with b-cells; and the black bars represent genes associated with b-cells, but not 
with epithelial cells. Note: due to the nature of RNA-Seq, error bars are not used when 
presenting RNA-Seq data.
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The pathways identified by the software analysis were then screened for biological significance 
and/or potential association with the observed morphological changes using GeneCards™ 
(http://www.genecards.org/), the NCBI gene information database 
(http://www.ncbi.nlm.nih.gov/gene), and reviewing available literature on each gene and 
pathway. Genes determined to be potentially biologically significant are listed in Table 2.
Table 2: Summarized results of literature review. Genes identified as upregulated by both RNA- 
Seq and qPCR are marked with green 'Up'. Genes identified as downregulated by both RNA-Seq 
and qPCR are marked with red 'Down'. Genes with a single asterisk (ANXA2, BCL2, CXCR7, 
PRKCD, & UTRN) indicate that qPCR was not performed. Genes with two asterisks (ERBB2 & 
TGFB1) indicate that RNA-Seq identified them as being up- or downregulated, but qPCR showed 
no difference in expression between RTA+ and RTA- cells. Neither BCL2 nor TNFa were 
themselves identified by RNA-Seq as being differentially expressed in RTA+ cells compared to 
RTA- cells, but were nonetheless included in the literature review. BCL2 was included because 
two similar genes [BCL2-like protein 1 (BCL2L1); and BCL2-like protein 2 (BCL2L2)] were 
identified by RNA-Seq as upregulated; and much more information is available about BCL2 than 
either BCL2L1 or BCL2L2. Similarly, TNFa was included because RNA-Seq identified the closely 
related TNFSF12 (TNF superfamily member 12) as upregulated in RTA+ cells.
Gene Change in 
RTA+ Cells
Effect References
ANXA2 Down* Deregulation associated with metastasis; 
cytoskeletal attachment and organization; 
endocytosis and exocytosis
[Gerke and Moss, 2002; 
Hayes et al., 2004; Leal 
et al., 2015]
BCL2 (Up)* Overexpression blocks apoptosis [Anderson et al., 2014]
BRCA1 Down Tumor suppressor gene involved in DNA repair [Mersch et al., 2015]
CCL2 Down Also called monocyte chemoattractant protein-1 
(MCP-1); chemoattractant for natural killer cells, 
monocytes, and T lymphocytes; proinflammatory; 
proangiogenic; KSHV induced over-expression of 
CCL2 is accompanied by capillary-like structure 
formation
[Caselli et al., 2006; 
Conti and Rollins, 2004; 
Ohta et al., 2002]
CD47 Down Regulates cell-cell adhesion in MDCK cells by 
reorganizing the actin cytoskeleton; important 
signaling molecule in the tumor microenvironment
[Shinohara et al., 2006; 
Sick et al., 2012]
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Table 2 continued
Gene Change in 
RTA+ Cells
Effect References
CGN Up Involved in regulating gene expression during 
epithelial differentiation; regulates RHO GTPases; 
regulates claudin expression in MDCK cells; 
directly interacts with the actin cytoskeleton
[Aijaz et al., 2005; Citi et 
al., 1989, 2009, 2012; 
Guillemot and Citi,
2006; Guillemot et al., 
2004; Matter and Balda, 
2003]
COL1A2 Up Component of the extracellular matrix protein 
type 1 collagen
[Elliott et al., 2003]
CTSD Down Overexpressed in breast cancer cells; degrades the 
extracellular matrix, thereby releasing ECM-bound 
basic fibroblastic growth factor
[Benes et al., 2008; 
Briozzo et al., 1991; 
Cavailles et al., 1993; 
Laurent-Matha et al., 
2005; Liaudet-Coopman 
et al., 2006; Rochefort 
et al., 1989; Takei et al., 
1997]
CTSS Down Knockout impairs tumor formation and 
angiogenesis; necessary for MHC class II peptide 
processing
[Gocheva et al., 2006; 
Shi et al., 1999; Wang et 
al., 2005]
CXCL10 Down Overexpressed in autoimmune diseases; inhibits 
angiogenesis by binding to CXCR3
[Antonelli et al., 2014; 
Strieter et al., 2005; 
Yang and Richmond, 
2004]
CXCR7 Down* Binds to CXCL12 to promote angiogenesis; 
expressed in primitive erythroid cells in embryos, 
but not expressed in leukocytes in adults
[Berahovich et al., 2010; 
Strieter et al., 2005]
DSG3 Up Adhesion molecule in desmosomes; regulates cell­
cell adhesion and actin cytoskeleton organization; 
overexpressed in some cancers; silencing DSG3 
slows tumor growth;
[Chen et al., 2013; Chen 
et al., 2007; Man Tsang 
et al., 2012; Sumigray et 
al., 2014; Zhurinsky et 
al., 2000]
EDN1 Down Growth factor that activates numerous signaling 
pathways, including MAPK and EGFR pathways; 
regulates genes associated with adhesion, 
angiogenesis, and apoptosis;
[Bagnato et al., 2008; 
Stow et al., 2011]
EGF Down Regulates gene expression in breast cancer cells by 
binding to EGFR and ERBB2 receptors; causes actin 
polymerization and membrane ruffling by 
activating RHO GTPases
[Barry, 2005; Boonstra, 
1995; Frusic-Zlotkin et 
al., 2006; Zhurinsky et 
al., 2000]
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Table 2 continued
Gene Change in 
RTA+ Cells
Effect References
ERBB2 Up** Overexpressed in some breast cancers; 
overexpression is associated with increased 
aggressiveness; regulates gene expression by 
phosphorylating specific transcription factors in 
response to EGF
[Barry, 2005]
LAMC2 Up Extracellular matrix component; typically 
expressed in epithelial cells
[Colognato and 
Yurchenco, 2000]
MAP2K1 Down Increased activation causes dedifferentiation in 
MDCK cells; inhibition of MAP2K1 in Ras- 
transformed MDCK cells restores the lost epithelial 
morphology
[Chen et al., 2000; 
Schramek et al., 1997]
MMP9 Down Degrades extracellular matrix proteins; required 
for the release of vascular endothelial growth 
factor (VEGF) during long bone development; 
MMP9-null mice show reduced angiogenesis; 
increases tumor invasiveness and angiogenesis; 
inhibited by TIMP's
[Baker, 2002; Chen et 
al., 2013; Coussens, 
2002; McCawley and 
Matrisian, 2001; Nagase 
et al., 2006; Patterson 
and Sang, 1997; Seo et 
al., 2003; Visse and 
Nagase, 2003; Yu and 
Stamenkovic, 2000]
MUC1 Down Overexpression blocks adhesion to the 
extracellular matrix; forms part of the mucosal 
barrier to viral and bacterial infections; interacts 
with ERBB2 during mammary gland development
[Gendler, 2001; Kumar 
et al., 2014; Ligtenberg 
et al., 1992; McAuley et 
al., 2007; Wesseling et 
al., 1995]
PDPN Up Lymphatic endothelial cell marker; promotes 
tumor invasion by remodeling the actin 
cytoskeleton; expression is induced by PROX1 
transcription factor
[Hong et al., 2002; Pan 
et al., 2014; Petrova et 
al., 2002; Rudzinska et 
al., 2014; Shindo et al., 
2014; Wakisaka et al., 
2015; Weninger et al., 
1999; Wicki et al., 2006]
PLAU Up Involved in suppressing regulatory T cells; 
produced by endothelial cells during angiogenesis; 
inhibition of PLAU disrupts metastasis in chick 
embryos; increased expression correlates with 
poor prognosis in numerous types of cancer
[Balcerzyk et al., 2011; 
He et al., 2012; Ulisse et 
al., 2009]
PRKCD Up* Activates the transcription factor estrogen-related 
receptor a (ERRa) in response to EGF signaling
[Barry, 2005]
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Table 2 continued
Gene Change in 
RTA+ Cells
Effect References
TGFB1 Down** Induces epithelial to mesenchymal transition in 
hepatocytes; promotes angiogenesis and tumor 
invasiveness following activation by MMP9; 
promotes migration, invasion, and filopodia 
formation in spindle-shaped tumor cells by 
increasing fascin expression; involved in 
differentiation and vascular remodeling
[Kojima et al., 2007; Sun 
et al., 2011; Wang et al., 
2004; Yu and 
Stamenkovic, 2000]
TIMP1
&
TIMP2
Up Prevent MMP's from degrading the extracellular 
matrix; inhibit angiogenesis independent of MMP 
blocking actions
[Baker, 2002; Guedez et 
al., 1998; Nagase et al., 
2006; Seo et al., 2003; 
Visse and Nagase, 2003]
TNFa (Up) Proinflammatory cytokine; involved in cancer- 
related anemia; promotes apoptosis & 
proliferation
[Kalyani and Jamil, 2015; 
Lu et al., 2014; Siggs et 
al., 2012]
UTRN Up* Involved in B-cell adhesion to the extracellular 
matrix; knockdown inhibits adhesion
[Belanto et al., 2014; 
Costantini et al., 2009]
That screening identified 10 genes clustered in three categories that were potentially 
biologically significant. Of these 10 genes, 7 were associated with ECM creation and 
destruction; 1 was associated with cellular adhesion to the ECM; and 2 were associated with 
epithelial or endothelial differentiation. The RNA-Seq results for the 10 genes were then 
verified by qPCR (Fig 7).
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Fig 7: Gene expression fold-changes fo r potentially biologically significant genes. Differences are 
between RTA+ and RTA- cell lines as measured by qPCR fo r genes identified as potentially 
biologically significant. Error bars represent propagated standard errors. White bars indicate 
genes involved in ECM remodeling. Striped bars indicate cells involved in epithelial/endothelial 
differentiation. RTA suppressed genes that degrade or block extra cellular matrix (MUC1, CTSD, 
CTSS, & MMP9). At the same time, it also increased expression of extra cellular matrix 
maintenance factors; including both extra cellular matrix components (COL1A2 & LAMC2) and 
degradation inhibitors (TIMP1 & TIMP2). Additionally, a gene involved in epithelial 
dedifferentiation (MAP2K1) was down-regulated; while podoplanin (PDPN), a cell marker seen 
only in lymphatic endothelium, was up-regulated.
2.4.4. ECM Regulation
Three complimentary pathways related to ECM regulation were altered by RTA. ECM 
degradation genes were down-regulated; genes that block ECM degradation were up­
regulated; and ECM components themselves were up-regulated (Fig. 7).
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2.4.4.1. Suppression of ECM Degradation Genes
Three genes whose products are involved in degrading the ECM were significantly down­
regulated by RTA. Matrix Metallopeptidase 9 (MMP9) was down-regulated over 50-fold in the 
RTA+ cells. MMPs are a family of zinc-dependent proteases instrumental in the breakdown of 
the ECM, as well as playing roles in a variety of other cellular functions [Nagase et al., 2006]. 
Additionally, cathepsins D (CTSD) and S (CTSS) were down-regulated 2.4- and 15-fold 
respectively. Both cathepsins degrade ECM components. CTSD breaks down ECM proteins 
collagen and fibronectin releasing the ECM-bound cytokine basic fibroblast growth factor 
(bFGF) which promotes further degradation of the ECM [Briozzo et al., 1991]. Suppression of 
CTSS decreases tumor invasiveness [Gocheva et al., 2006] and angiogenesis [Wang et al., 2005].
2.4.4.2. ECM Degradation Blocked by Tissue Inhibitors of Metalloproteases (TIMPs)
In addition to suppressing transcription of genes involved in breaking down the ECM, RTA's 
presence within MDCK cells stimulated transcription of proteins that inhibit ECM degradation. 
Tissue inhibitors of metalloproteases (TIMPs) are one such family of proteins. Expression of 
TIMP1 and TIMP2 was increased 5.4-fold and 4.2-fold respectively. Both have the ability to bind 
to and inhibit all MMPs, thereby blocking their degradation of the ECM components [Baker, 
2002]. The increase in TIMP expression reinforces the decrease in MMP9 expression to further 
suppress ECM degradation in RTA+ cells.
2.4.4.3. Increased Expression of ECM Components
As well as inhibiting the breakdown of ECM already present, RTA also increased the expression 
of several genes coding for ECM structural proteins themselves. Expression of the LAMC2 
component of laminin was increased 3.6-fold, and expression of the type 1 collagen component 
COL1A2 was increased 8.7-fold.
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2.4.4.4. Cell-Cell and Cell-ECM Adhesion
Mucin 1 (aka Episialin, or MUC1) expression was 78-fold lower in RTA+ cells. MUC1 is a 
transmembrane protein frequently expressed by epithelial cells as well as a number of 
hematopoietic cells [Gendler, 2001], and is overexpressed in many carcinomas [Wesseling et al., 
1995]. Overexpression of MUC1 has been shown to block both cell-cell and cell-matrix adhesion 
[Ligtenberg et al., 1992; Wesseling et al., 1995]. MUC1 also forms part of the mucus layers that 
contribute to the prevention of microbial and viral infection [McAuley et al., 2007].
2.4.5. Differentiation of Epithelial/Endothelial Cells
MAP2K1 (mitogen activated protein kinase kinase 1) is involved in epithelial differentiation. 
Increased MAP2K1 activity leads to epithelial dedifferentiation in MDCK cells [Schramek et al., 
1997] and MAP2K1 was found to be down-regulated 2.4-fold by RTA. Suppression of MAP2K1 
was further shown to reverse this dedifferentiation and resulted in restoration of the lost 
epithelial morphology [Chen et al., 2000]. RTA's ability to suppress MAP2K1 is therefore likely 
to play a role in MDCK reprogramming.
Podoplanin (PDPN) is a lymphatic endothelial specific marker whose presence in spindle cells 
was used as evidence that spindle cells originate from lymphatic endothelial cells [Weninger et 
al., 1999]. Podoplanin was up-regulated 13-fold by RTA.
2.5. Discussion
In this study we identified potential mechanisms by which KSHV was able to induce a spindle­
like morphology in host cells. Previous work in our lab had shown that MDCK cells transfected 
with a plasmid vector coding for KSHV's lytic switch protein (RTA) were reprogrammed to 
display an elongated shape similar to the spindle cells that predominate in KS tumors. RTA is a 
transcriptional transactivator and hence the mechanism by which it effects the change in cell 
shape is likely by modulating gene expression in its host cell. Of the 180 genes up- or down­
regulated by RTA, 10 were identified as potentially biologically significant due to their 
associations with ECM binding and remodeling and/or their identity as BEC- or LEC-specific
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markers. These findings support our hypothesis that RTA was effecting the morphological 
reprogramming of host cells by altering the levels of transcription in signaling pathways 
associated with regulating cell shape. However, our results can only support a correlation 
between changes in expression of those 10 genes and the observed changes in cell morphology. 
Establishing a causative relationship will require selectively targeting each of those genes to 
counteract the influence of RTA and observing the resulting effect on phenotype.
Not only does RTA modulate expression of genes involved in regulating cell shape (as we 
predicted), but it also increased expression of the lymphatic endothelial specific protein 
podoplanin and the blood endothelial specific protein laminin. These results concur with the 
finding that KSHV infection of either lymphatic endothelial cells (LECs) or blood endothelial cells 
(BECs) causes those cells to be reprogrammed to display an intermediate gene expression 
profile that is ~70% LEC-specific and ~30% BEC-specific [Wang et al., 2004]. One limitation of 
the previous studies demonstrating that KSHV has the ability to reprogram host cells to express 
lymphatic endothelial specific proteins was that they involved infecting cell cultures with KSHV, 
rather than transfecting them with a single viral protein as in our study. The effect of that 
difference was that the presence of the entire virus in the host cells led to a much larger 
number of gene expression changes; thereby making it much more difficult to identify causal 
relationships. For example, expression of the master lymphatic vascular development gene 
PROX1 in blood endothelial cells (BECs) causes those cells to express podoplanin as well as a 
number of other lymphatic-specific proteins [Hong et al., 2002]. However, when previous 
whole-virus studies found that infecting BECs with KSHV caused increased expression of both 
PROX1 and podoplanin, they found that knocking down PROX1 did not fully reduce podoplanin 
transcription levels back to their initial pre-KSHV levels; indicating that additional factors were 
driving the increase in podoplanin. Our results indicate that RTA likely causes at least a portion 
of the remaining unexplained increase in podoplanin expression. Determining whether RTA is 
the sole remaining factor would require knocking down expression of both PROX1 and RTA in 
KSHV infected cells and measuring the resulting levels of podoplanin transcription in those cells 
relative to KSHV-naive cells.
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In this study we demonstrated that RTA is capable of reprogramming host cells to adopt a 
spindle-like morphology, as well as inducing expression of LEC and BEC specific proteins. Taken 
together, these findings open the possibility of a non-endothelial origin for KS spindle cells. The 
current consensus for an endothelial (rather than B-cell) origin for spindle cells is based on 
morphological similarities between spindle cells and endothelial cells. In order for spindle cells 
to originate from KSHV-infected B-cells, the virus would have to reprogram the cells to display a 
spindle cell-like phenotype. Previous work in our lab showed that when PEL derived 
lymphoblastic BCBL-1 cells were treated with phorbol ester to induce lytic replication, a portion 
of those cells adopted a spindle cell-like phenotype; and that ectopic expression of RTA in 
KSHV-naive cells caused those cells to adopt a spindle cell-like phenotype (J. Chen, unpublished 
work, 2014). The results of this study further support those findings by identifying a set of gene 
expression changes induced by RTA that may be causing that phenotypical reprogramming. 
Further work is needed to determine whether the effects found in vitro also exist in vivo. If so, 
then it is possible that, despite their distinctly different phenotypes, KS and PEL may share a B- 
cell origin.
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Chapter 3. General Conclusion
The morphological similarities between KS spindle cells and endothelial cells supported the 
hypothesis that spindle cells originated form KSHV-infected endothelium. However, previous 
work in our lab found that KSHV was capable of reprogramming lymphoblastic BCBL-1 cells in 
vitro, causing a portion of them to adopt a spindle cell-like phenotype following lytic 
reactivation; and that ectopic expression of RTA in KSHV-naive cells also induced a spindle cell­
like phenotype. These observations suggested the possibility that spindle cells may originate 
from B-cells (or other non-endothelial cells) in vivo. The present study investigated the 
potential mechanisms by which RTA (KSHV's lytic switch protein) could be causing that 
reprogramming. Analysis of the gene expression changes induced by RTA identified 10 genes 
potentially responsible for the reprogramming.
Morphological reprogramming being a part of KS formation explains a number of previously 
puzzling aspects of KS biology. For example, the idea that KS is formed when 
immunosuppression causes the virus in latently infected endothelial cells to reactivate ignores 
the fact that KSHV is incapable of forming a stable latent infection in those cells [Grundhoff and 
Ganem, 2004]. The only cells known to permit a stable latent KSHV infection are B-cells. If KS 
spindle cells form after infected B-cells have been reprogrammed into endothelial-type cells, 
then it would be evident why the virus is frequently lost from spindle cells in vitro and in vivo. 
Since endothelial cells are not conducive to KSHV latency, once the cell is reprogrammed the 
latent infection may become unstable and be subsequently lost. Morphological reprogramming 
may also explain why KS is much more prevalent than PEL. If the same lytic reactivation process 
is responsible for both the malignant transformation and the morphological reprogramming, 
then PEL would have to be the result of the lytic reactivation process transforming the host cell, 
but somehow failing to morphologically reprogram it. If both processes share the same trigger, 
then extraneous conditions would be required to allow one of them to be activated while the 
other was not.
In addition to their obvious application to KS and KSHV research, the results of this study have a 
number of other potential applications as well. For example, because of the narrow focus of
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this study on the effects caused by ectopic expression of a single viral protein, the list of 
interesting genes was much smaller than those typically generated by broadly focused studies 
(such as GWAS based studies). Not only does that simplify the process of determining which 
gene expression changes are driving the phenotypic changes, it also ensures that those gene 
expression changes are actually being caused by RTA. That level of detail in defining triggers 
and mechanisms involved in cellular reprogramming may be useful in tissue engineering 
settings.
And lastly, KS is unusual in that it is located approximately halfway along the continuum 
between healthy cells and cancer cells. Like typical cancers, KS proliferates and invades other 
tissues; but unlike typical cancers, KS is not genetically unstable and it requires external growth 
factors to proliferate. That makes it uniquely placed to serve as a model for the investigation of 
the intermediate steps in malignant transformation. There is a significantly long list of both 
healthy and cancerous cells to choose from for research purposes, but very few partially 
transformed cells like KS. The lack of partially transformed cells, combined with the fact that in 
vivo transformation requires a number of steps that often occur months or years apart, makes 
studying the process of oncogenesis very difficult. Therefore, one of the most valuable aspects 
of KS research is that it can give us insights into the process of malignant transformation which 
may be applicable to a vast number of other types of cancer.
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Appendix A 
GeneCards -  Set Distiller Results
Table A-1: Genes input into GeneCards Set Distiller Software
Genes Used in Set_______________________________________________________________________
ABCB1, ACTB, ADCY6, ADRA1B, ANKHD1, ANXA13, ANXA2, ANXA4, AP3S2, APP, APTX, ARG2,
ARHGEF2, ATP1A1, ATP2A2, ATP6V0E1, ATP7B, AVPR2, BCL2L1, BCL2L2, BEX4, BIRC3, BRCA1, CA2, 
CASP3, CCL17, CCL2, CCL20, CCL24, CCL7, CD40, CD47, CD97, CGN, CLDN2, CLDN3, CLIC2, CLN3, 
CLNS1A, COL1A2, COX16, CPNE1, CSF2, CTSC, CTSD, CTSS, CXCL10, CYB5R1, CYP4A11, DAG1, DNAJA1, 
DSG3, EBAG9, EDN1, EFNB2, EGF, EIF4A1, EIF4EBP3, EPB41, ERBB2, ESRRA, F2RL1, FASTK, FGFR1OP2, 
FLCN, FOSB, FUT10, FXYD2, FZD6, GALK1, GDI1, GDI2, GNA11, GPX8, GSTA4, GSTP1, GUCA2A, 
GUCY1B3, GUSB, H19, HLA-DMA, HLA-DMB, HLA-DQB1, HLA-DRB1, HMGN2, HSPB8, IL13RA2, KDM5C, 
KRT14, KRT19, LAMC2, LGALS9, LIFR, LMAN2, MAL, MAP2K1, MAPK14, MCPH1, MGMT, MMP11, 
MMP9, MSX2, MT1E, MT2A, MUC1, NACA, NFKBIL1, NPC1L1, OTUB1, PDPN, PFDN1, PFDN5, PFDN6, 
PLA2G15, PLA2G7, PLAU, PNN, PODXL, POFUT1, POLDIP2, PPP1CA, PPP1CB, PRKACA, PRKCD, PRKDC, 
PRR5, PSMB8, PSMB9, PTGER2, RAB11A, RAB1A, RAB2A, RBM47, RHBDF2, RHPN2, RPL27A, RPS10, 
RPS15A, RPS24, SELK, SELT, SEPP1, SETMAR, SLC1A1, SLC35A3, SLC35B2, SLC35C1, SNAI2, SNRPB2, 
SNRPG, SOCS3, ST13, TBPL1, TBX2, TCOF1, TES, TFF1, TGFB1, THADA, TIMP1, TIMP2, TMBIM6, 
TMEM47, TMEM57, TNFSF12, TXNRD1, UTRN, WFDC2, ZBED5, ZFPM2
Table A-2: GeneCards Set Distiller output showing a ranked listing of patterns identified in the input list
Descriptor Attribute type Score P Value Genes sharing this descriptor
tumors DISORDER 96 1.00E-16 ABCB1, ACTB, ANXA2, ANXA4, ARG2, 
ARHGEF2, ATP2A2, ATP7B, AVPR2, BCL2L1, 
BCL2L2, BIRC3, BRCA1, CA2, CASP3, CCL17, 
CCL2, CCL20, CCL24, CCL7, CD40, CD47, CD97, 
CGN, CLDN2, CLDN3, COL1A2, CSF2, CTSC, 
CTSD, CXCL10, DAG1, DSG3, EBAG9, EFNB2, 
EGF, EIF4A1, EPB41, ERBB2, ESRRA, F2RL1, 
FASTK, FLCN, FOSB, GALK1, GDI1, GSTP1, 
GUCA2A, GUSB, H19, HLA-DMA, HLA-DQB1, 
HLA-DRB1, HMGN2, IL13RA2, KRT14, KRT19, 
LAMC2, LGALS9, LIFR, MAL, MAP2K1, 
MAPK14, MGMT, MMP11, MMP9, MSX2, 
MT1E, MT2A, MUC1, NACA, PDPN, PLA2G7, 
PLAU, PNN, PODXL, PPP1CB, PRKCD, PRKDC, 
PSMB8, PSMB9, PTGER2, SEPP1, SNAI2, 
SOCS3, ST13, TES, TFF1, TGFB1, TIMP1, 
TIMP2, TMBIM6, TNFSF12, TXNRD1, WFDC2, 
ZFPM2
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Table A-2 continued
Descriptor Attribute type Score P Value Genes sharing this descriptor
protein binding GO_MOLEC_F
UNC
93 1.00E-16 ABCB1, ACTB, ADCY6, ANKHD1, ANXA2, APP, 
APTX, ARHGEF2, ATP1A1, ATP2A2, ATP7B, 
AVPR2, BCL2L1, BCL2L2, BIRC3, BRCA1, CA2, 
CASP3, CCL20, CD40, CD47, CD97, CGN,
CLIC2, CLN3, CLNS1A, COL1A2, CSF2, CTSC, 
CTSD, CXCL10, DAG1, DNAJA1, EDN1, EFNB2, 
EGF, EIF4A1, EIF4EBP3, EPB41, ERBB2, ESRRA, 
F2RL1, FASTK, FLCN, FZD6, GDI1, GDI2,
GSTP1, HSPB8, KRT14, KRT19, MAL, MAP2K1, 
MAPK14, MCPH1, MMP9, MSX2, MT2A, 
MUC1, NACA, NFKBIL1, NPC1L1, OTUB1, 
PFDN5, PLAU, PODXL, PPP1CA, PPP1CB, 
PRKACA, PRKCD, PRKDC, PSMB8, PSMB9, 
RAB11A, RAB1A, RPL27A, RPS10, SETMAR, 
SLC35A3, SNRPB2, SNRPG, SOCS3, ST13,
TBX2, TCOF1, TFF1, TGFB1, TIMP1, TIMP2, 
TNFSF12, TXNRD1, UTRN, ZFPM2
Placenta EXPRESSION 87 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BEX4, 
CCL2, CD47, CD97, CLDN3, CLN3, CLNS1A, 
COL1A2, CTSC, CTSD, CYB5R1, DAG1, DNAJA1, 
EBAG9, EFNB2, EIF4A1, ERBB2, FASTK, FUT10, 
FZD6, GDI1, GDI2, GNA11, GSTA4, GSTP1, 
GUCA2A, GUSB, H19, HLA-DMB, HLA-DRB1, 
HMGN2, HSPB8, KDM5C, KRT14, KRT19, 
LGALS9, LMAN2, MAL, MAP2K1, MMP11, 
MSX2, MT1E, MT2A, NACA, OTUB1, PFDN1, 
PFDN5, PLAU, PNN, PODXL, PPP1CA, PPP1CB, 
PRKACA, RAB11A, RAB1A, RAB2A, RBM47, 
RPL27A, RPS10, RPS15A, RPS24, SELK, SELT, 
SEPP1, SNAI2, SNRPB2, SNRPG, SOCS3, ST13, 
TBPL1, TBX2, TES, TFF1, TIMP1, TIMP2, 
TMBIM6, TXNRD1, ZBED5
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Table A-2 continued
Descriptor Attribute type Score P Value Genes sharing this descriptor
Whole Blood EXPRESSION 86 1.00E-16 ACTB, ANXA2, ANXA4, APP, ATP1A1, ATP2A2, 
ATP6V0E1, BCL2L1, BEX4, BIRC3, CASP3,
CCL2, CD47, CD97, CLNS1A, CTSC, CTSD, CTSS, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
F2RL1, FASTK, FOSB, FUT10, GDI1, GDI2, 
GNA11, GSTA4, GSTP1, GUCA2A, GUSB, H19, 
HLA-DMA, HLA-DMB, HLA-DQB1, HLA-DRB1, 
HMGN2, KDM5C, LGALS9, LMAN2, MAL, 
MAP2K1, MAPK14, MMP9, MT1E, MT2A, 
NACA, OTUB1, PFDN1, PFDN5, PNN, PPP1CA, 
PPP1CB, PRKACA, PRKCD, PSMB8, PSMB9, 
PTGER2, RAB11A, RAB1A, RAB2A, RBM47, 
RHBDF2, RPL27A, RPS10, RPS15A, RPS24, 
SELK, SELT, SNRPB2, SNRPG, SOCS3, ST13, 
TBPL1, TES, TFF1, TGFB1, TIMP1, TIMP2, 
TMBIM6, TNFSF12, TXNRD1, ZBED5
B Lymphoblasts EXPRESSION 86 1.00E-16 ACTB, ANKHD1, ANXA2, ANXA4, APTX, 
ARHGEF2, ATP1A1, ATP2A2, ATP6V0E1, 
BCL2L1, BEX4, BIRC3, BRCA1, CD40, CD47, 
CD97, CLNS1A, CPNE1, CTSC, CTSD, CTSS, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FUT10, GDI1, GDI2, GSTA4, GSTP1, 
GUCA2A, GUSB, H19, HLA-DMA, HLA-DMB, 
HLA-DQB1, HLA-DRB1, HMGN2, KDM5C, 
LGALS9, LMAN2, MAL, MAP2K1, MAPK14, 
MT1E, MT2A, NACA, OTUB1, PFDN1, PFDN5, 
PFDN6, PNN, POLDIP2, PPP1CA, PPP1CB, 
PRKACA, PRKCD, PRKDC, PSMB8, PSMB9, 
RAB11A, RAB1A, RAB2A, RHBDF2, RPL27A, 
RPS10, RPS15A, RPS24, SELK, SELT, SNRPB2, 
SNRPG, SOCS3, ST13, TBPL1, TCOF1, TES, 
TFF1, TGFB1, TIMP1, TIMP2, TMBIM6, 
TXNRD1, ZBED5
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Table A-2 continued
Descriptor Attribute type Score P Value Genes sharing this descriptor
Myeloid EXPRESSION 84 1.00E-16 ACTB, ANKHD1, ANXA2, ANXA4, APP, 
ARHGEF2, ATP1A1, ATP2A2, ATP6V0E1, 
BCL2L1, BEX4, CCL2, CD47, CD97, CLN3, 
CLNS1A, CTSC, CTSD, CTSS, CYB5R1, DAG1, 
DNAJA1, EBAG9, EIF4A1, FASTK, FOSB, FUT10, 
GDI1, GDI2, GNA11, GSTP1, GUCA2A, GUSB, 
H19, HLA-DMA, HLA-DMB, HLA-DQB1, HLA- 
DRB1, HMGN2, KDM5C, LGALS9, LMAN2,
MAL, MAP2K1, MAPK14, MT1E, MT2A, NACA, 
OTUB1, PFDN1, PFDN5, PNN, PPP1CA, 
PPP1CB, PRKACA, PRKCD, PSMB8, PSMB9, 
PTGER2, RAB11A, RAB1A, RAB2A, RBM47, 
RHBDF2, RPL27A, RPS10, RPS15A, RPS24, 
SELK, SELT, SNRPB2, SNRPG, SOCS3, ST13, 
TBPL1, TES, TFF1, TGFB1, TIMP1, TIMP2, 
TMBIM6, TNFSF12, TXNRD1, ZBED5
Monocytes EXPRESSION 84 1.00E-16 ACTB, ANKHD1, ANXA2, ANXA4, APP, 
ARHGEF2, ATP1A1, ATP2A2, ATP6V0E1, 
BCL2L1, BEX4, CCL2, CD47, CD97, CLNS1A, 
CTSC, CTSD, CTSS, CYB5R1, DAG1, DNAJA1, 
EBAG9, EIF4A1, FASTK, FOSB, FUT10, GDI1, 
GDI2, GNA11, GSTP1, GUCA2A, GUSB, H19, 
HLA-DMA, HLA-DMB, HLA-DQB1, HLA-DRB1, 
HMGN2, KDM5C, LGALS9, LMAN2, MAL, 
MAP2K1, MAPK14, MT1E, MT2A, NACA, 
OTUB1, PFDN1, PFDN5, PLA2G7, PNN, 
PPP1CA, PPP1CB, PRKACA, PRKCD, PSMB8, 
PSMB9, PTGER2, RAB11A, RAB1A, RAB2A, 
RBM47, RHBDF2, RPL27A, RPS10, RPS15A, 
RPS24, SELK, SELT, SNRPB2, SNRPG, SOCS3, 
ST13, TBPL1, TES, TFF1, TGFB1, TIMP1, 
TIMP2, TMBIM6, TNFSF12, TXNRD1, ZBED5
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Table A-2 continued
Descriptor Attribute type Score P Value Genes sharing this descriptor
NK Cells EXPRESSION 84 1.00E-16 ABCB1, ACTB, ANKHD1, ANXA2, ANXA4, APP, 
ARHGEF2, ATP1A1, ATP2A2, ATP6V0E1,
BCL2L1, BEX4, BIRC3, CCL2, CD47, CD97, 
CLNS1A, CTSC, CTSD, CTSS, CYB5R1, DAG1, 
DNAJA1, EBAG9, EIF4A1, FASTK, FOSB, FUT10, 
GDI1, GDI2, GNA11, GSTP1, GUCA2A, GUSB, 
H19, HLA-DMA, HLA-DMB, HLA-DRB1,
HMGN2, KDM5C, LGALS9, LMAN2, MAL, 
MAP2K1, MAPK14, MT1E, MT2A, NACA, 
OTUB1, PFDN1, PFDN5, PNN, PPP1CA, PPP1CB, 
PRKACA, PRKCD, PRR5, PSMB8, PSMB9, 
PTGER2, RAB11A, RAB1A, RAB2A, RHBDF2, 
RPL27A, RPS10, RPS15A, RPS24, SELK, SELT, 
SNRPB2, SNRPG, SOCS3, ST13, TBPL1, TES, 
TFF1, TGFB1, TIMP1, TIMP2, TMBIM6,
TXNRD1, UTRN, ZBED5
Fetal Lung EXPRESSION 83 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, ATP1A1, 
ATP2A2, ATP6V0E1, BCL2L1, BEX4, CCL2, 
CCL20, CD47, CLDN3, CLNS1A, COL1A2, CTSC, 
CTSD, CYB5R1, DAG1, DNAJA1, EBAG9, EDN1, 
EFNB2, EIF4A1, FASTK, FUT10, FZD6, GDI1, 
GDI2, GNA11, GSTA4, GSTP1, GUCA2A, GUSB, 
H19, HLA-DMB, HLA-DRB1, HMGN2, HSPB8, 
KDM5C, KRT19, LGALS9, LMAN2, MAL, 
MAP2K1, MT1E, MT2A, MUC1, NACA, OTUB1, 
PFDN1, PFDN5, PNN, PODXL, PPP1CA, PPP1CB, 
PRKACA, RAB11A, RAB1A, RAB2A, RBM47, 
RPL27A, RPS10, RPS15A, RPS24, SELK, SELT, 
SEPP1, SNRPB2, SNRPG, SOCS3, ST13, TBPL1, 
TBX2, TES, TFF1, TIMP1, TIMP2, TMBIM6, 
TXNRD1, WFDC2, ZBED5
homeostasis/
metabolism
phenotype
PHENOTYPE 83 1.00E-16 ABCB1, ACTB, ADCY6, ADRA1B, ANXA2, APP, 
APTX, ARG2, ATP1A1, ATP2A2, ATP7B, AVPR2, 
BCL2L1, BCL2L2, BIRC3, BRCA1, CA2, CASP3, 
CCL2, CD40, CD47, CGN, CLDN2, CLN3, CSF2, 
CTSC, CTSD, CTSS, CXCL10, CYP4A11, DAG1, 
EDN1, EFNB2, EPB41, ERBB2, ESRRA, F2RL1, 
FASTK, FLCN, GALK1, GDI1, GNA11, GSTA4, 
GUCY1B3, GUSB, HLA-DQB1, HSPB8, IL13RA2, 
KRT14, LIFR, MAP2K1, MAPK14, MGMT, 
MMP11, MMP9, MT2A, MUC1, NACA, NPC1L1, 
PDPN, PLA2G15, PLAU, PNN, PODXL, PRKACA, 
PRKCD, PRKDC, PTGER2, RHBDF2, SELK, SELT, 
SEPP1, SLC1A1, SLC35C1, SOCS3, TBX2, TFF1, 
TGFB1, TIMP1, TIMP2, TMBIM6, UTRN, ZFPM2
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Table A-2 continued
Descriptor Attribute type Score P Value Genes sharing this descriptor
Dentritic Cells EXPRESSION 82 1.00E-16 ACTB, ANKHD1, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BEX4, 
BIRC3, CCL2, CD47, CD97, CLNS1A, CTSC, CTSD, 
CTSS, CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FOSB, FUT10, GDI1, GDI2, GNA11, 
GSTP1, GUCA2A, GUSB, H19, HLA-DMA, HLA- 
DMB, HLA-DQB1, HLA-DRB1, HMGN2, KDM5C, 
LGALS9, LMAN2, MAL, MAP2K1, MAPK14, 
MT1E, MT2A, NACA, OTUB1, PFDN1, PFDN5, 
PNN, PPP1CA, PPP1CB, PRKACA, PRKCD,
PSMB8, PSMB9, RAB11A, RAB1A, RAB2A, 
RBM47, RHBDF2, RPL27A, RPS10, RPS15A, 
RPS24, SELK, SELT, SNRPB2, SNRPG, SOCS3, 
ST13, TBPL1, TES, TFF1, TGFB1, TIMP2,
TMBIM6, TNFSF12, TXNRD1, ZBED5
T Cells (CD8+) EXPRESSION 81 1.00E-16 ABCB1, ACTB, ANKHD1, ANXA2, ANXA4, APP, 
ARHGEF2, ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, 
BEX4, BIRC3, CD47, CD97, CLNS1A, CTSC, CTSD, 
CTSS, CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FOSB, FUT10, GDI1, GDI2, GSTP1, 
GUCA2A, GUSB, H19, HLA-DMB, HLA-DRB1, 
HMGN2, KDM5C, LGALS9, LMAN2, MAL, 
MAP2K1, MAPK14, MT1E, MT2A, NACA,
OTUB1, PFDN1, PFDN5, PNN, PPP1CA, PPP1CB, 
PRKACA, PRR5, PSMB8, PSMB9, PTGER2, 
RAB11A, RAB1A, RAB2A, RHBDF2, RPL27A, 
RPS10, RPS15A, RPS24, SELK, SELT, SNRPB2, 
SNRPG, SOCS3, ST13, TBPL1, TCOF1, TES, TFF1, 
TGFB1, THADA, TIMP1, TIMP2, TMBIM6, 
TXNRD1, ZBED5
B Cells EXPRESSION 81 1.00E-16 ACTB, ANKHD1, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BCL2L2, 
BEX4, BIRC3, CCL2, CD40, CD47, CD97, CLNS1A, 
CTSC, CTSD, CYB5R1, DAG1, DNAJA1, EBAG9, 
EIF4A1, FASTK, FOSB, FUT10, GDI1, GDI2, 
GNA11, GSTP1, GUCA2A, GUSB, H19, HLA-DMA, 
HLA-DMB, HLA-DQB1, HLA-DRB1, HMGN2, 
KDM5C, LGALS9, LMAN2, MAL, MAP2K1, 
MAPK14, MT1E, MT2A, NACA, OTUB1, PFDN1, 
PFDN5, PNN, PPP1CA, PPP1CB, PRKACA, PRKCD, 
PSMB8, PSMB9, RAB11A, RAB1A, RAB2A, 
RHBDF2, RPL27A, RPS10, RPS15A, RPS24, SELK, 
SELT, SNRPB2, SNRPG, SOCS3, ST13, TBPL1, TES, 
TFF1, TGFB1, TIMP2, TMBIM6, TXNRD1, ZBED5
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Table A-2 continued
Descriptor Attribute type Score P Value Genes sharing this descriptor
Small Intestine EXPRESSION 80 1.00E-16 ACTB, ANXA13, ANXA2, ANXA4, APP, 
ARHGEF2, ATP1A1, ATP2A2, ATP6V0E1, 
BCL2L1, BEX4, CCL2, CD47, CLDN3, CLNS1A, 
COL1A2, CTSC, CTSD, CTSS, CYB5R1, DAG1, 
DNAJA1, EBAG9, EFNB2, EIF4A1, FASTK, 
FUT10, GDI1, GDI2, GNA11, GSTA4, GSTP1, 
GUCA2A, GUSB, H19, HLA-DMA, HLA-DMB, 
HLA-DRB1, HMGN2, HSPB8, KDM5C, KRT19, 
LGALS9, LMAN2, MAL, MAP2K1, MT1E, 
MT2A, NACA, OTUB1, PFDN1, PFDN5, PNN, 
PPP1CA, PPP1CB, PRKACA, PSMB8, PSMB9, 
RAB11A, RAB1A, RAB2A, RPL27A, RPS10, 
RPS15A, RPS24, SELK, SELT, SEPP1, SNRPB2, 
SNRPG, SOCS3, ST13, TBPL1, TES, TFF1, 
TIMP1, TIMP2, TMBIM6, TXNRD1, ZBED5
Tonsil EXPRESSION 80 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BEX4, 
BIRC3, CCL20, CD47, CLNS1A, COL1A2, CTSC, 
CTSD, CYB5R1, DAG1, DNAJA1, DSG3, EBAG9, 
EIF4A1, FASTK, FUT10, GDI1, GDI2, GSTA4, 
GSTP1, GUCA2A, GUSB, H19, HLA-DMA, HLA- 
DMB, HLA-DQB1, HLA-DRB1, HMGN2, HSPB8, 
KDM5C, KRT14, KRT19, LGALS9, LMAN2,
MAL, MAP2K1, MMP9, MT1E, MT2A, NACA, 
OTUB1, PFDN1, PFDN5, PNN, PPP1CA, 
PPP1CB, PRKACA, PSMB8, PSMB9, RAB11A, 
RAB1A, RAB2A, RHBDF2, RPL27A, RPS10, 
RPS15A, RPS24, SELK, SELT, SEPP1, SNRPB2, 
SNRPG, SOCS3, ST13, TES, TFF1, TIMP1, 
TIMP2, TMBIM6, TXNRD1, ZBED5
T Cells (CD4+) EXPRESSION 80 1.00E-16 ACTB, ANKHD1, ANXA2, ANXA4, APP, 
ARHGEF2, ATP1A1, ATP2A2, ATP6V0E1, 
BCL2L1, BEX4, BIRC3, CD47, CD97, CLNS1A, 
CTSC, CTSD, CTSS, CYB5R1, DAG1, DNAJA1, 
EBAG9, EIF4A1, FASTK, FOSB, FUT10, GDI1, 
GDI2, GSTP1, GUCA2A, GUSB, H19, HLA-DMA, 
HLA-DMB, HLA-DRB1, HMGN2, KDM5C, 
LGALS9, LMAN2, MAL, MAP2K1, MAPK14, 
MT1E, MT2A, NACA, OTUB1, PFDN1, PFDN5, 
PNN, PPP1CA, PPP1CB, PRKACA, PRR5, 
PSMB8, PSMB9, PTGER2, RAB11A, RAB1A, 
RAB2A, RHBDF2, RPL27A, RPS10, RPS15A, 
RPS24, SELK, SELT, SNRPB2, SNRPG, SOCS3, 
ST13, TBPL1, TCOF1, TES, TFF1, TGFB1,
TIMP1, TIMP2, TMBIM6, TXNRD1, ZBED5
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Thymus EXPRESSION 78 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BEX4, 
CCL2, CD47, CD97, CLNS1A, COL1A2, CTSC, 
CTSD, CYB5R1, DAG1, DNAJA1, EBAG9, 
EIF4A1, FASTK, FUT10, GDI1, GDI2, GNA11, 
GSTA4, GSTP1, GUCA2A, GUSB, H19, HLA- 
DMA, HLA-DMB, HLA-DRB1, HMGN2, HSPB8, 
KDM5C, KRT14, KRT19, LGALS9, LMAN2,
MAL, MMP9, MT1E, MT2A, NACA, OTUB1, 
PFDN1, PFDN5, PNN, PPP1CA, PPP1CB, 
PRKACA, PSMB8, PSMB9, RAB11A, RAB1A, 
RAB2A, RPL27A, RPS10, RPS15A, RPS24, SELK, 
SELT, SEPP1, SNRPB2, SNRPG, SOCS3, ST13, 
TBPL1, TES, TFF1, TIMP1, TIMP2, TMBIM6, 
TXNRD1, ZBED5
Retina EXPRESSION 78 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BCL2L2, 
BEX4, CA2, CCL2, CD47, CLNS1A, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FOSB, FUT10, GDI1, GDI2, GNA11, 
GSTA4, GSTP1, GUCA2A, GUSB, H19, HLA- 
DMB, HLA-DRB1, HMGN2, HSPB8, KDM5C, 
LGALS9, LMAN2, MAL, MAP2K1, MT1E,
MT2A, NACA, OTUB1, PDPN, PFDN1, PFDN5, 
PNN, PODXL, PPP1CA, PPP1CB, PRKACA, 
RAB11A, RAB1A, RAB2A, RPL27A, RPS10, 
RPS15A, RPS24, SELK, SELT, SEPP1, SNAI2, 
SNRPB2, SNRPG, SOCS3, ST13, TBPL1, TES, 
TFF1, TIMP1, TIMP2, TMBIM6, TMEM47, 
TXNRD1, ZBED5
Smooth Muscle EXPRESSION 78 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BCL2L2, 
CCL2, CCL7, CD47, CLNS1A, COL1A2, CTSC, 
CTSD, CYB5R1, DAG1, DNAJA1, EBAG9, EDN1, 
EIF4A1, FASTK, FUT10, FZD6, GDI1, GDI2, 
GNA11, GPX8, GSTA4, GSTP1, GUCA2A,
GUSB, H19, HLA-DMB, HLA-DRB1, HMGN2, 
HSPB8, KDM5C, LGALS9, LMAN2, MAL, 
MAP2K1, MT1E, MT2A, NACA, OTUB1,
PFDN1, PFDN5, PLAU, PNN, PPP1CA, PPP1CB, 
PRKACA, RAB11A, RAB1A, RAB2A, RPL27A, 
RPS10, RPS15A, RPS24, SELK, SELT, SLC35B2, 
SNAI2, SNRPB2, SNRPG, SOCS3, ST13, TBPL1, 
TES, TFF1, TIMP1, TIMP2, TMBIM6, TXNRD1, 
ZBED5
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Salivary Gland EXPRESSION 78 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BEX4, 
CCL2, CD47, CLNS1A, COL1A2, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
ESRRA, FASTK, FUT10, FXYD2, GDI1, GDI2, 
GNA11, GSTA4, GSTP1, GUCA2A, GUSB, H19, 
HLA-DMA, HLA-DMB, HLA-DRB1, HMGN2, 
HSPB8, KDM5C, KRT14, KRT19, LGALS9, 
LMAN2, MAL, MAP2K1, MT1E, MT2A, NACA, 
NFKBIL1, OTUB1, PFDN1, PFDN5, PNN, 
PPP1CA, PPP1CB, PRKACA, RAB11A, RAB1A, 
RAB2A, RPL27A, RPS10, RPS15A, RPS24, SELK, 
SELT, SEPP1, SNRPB2, SNRPG, SOCS3, ST13, 
TES, TFF1, TIMP1, TIMP2, TMBIM6, TXNRD1, 
WFDC2, ZBED5
Pineal (Day) EXPRESSION 78 1.00E-16 ACTB, ANXA2, ANXA4, AP3S2, APP, APTX, 
ARHGEF2, ATP1A1, ATP2A2, ATP6V0E1, 
BCL2L1, BCL2L2, BEX4, CA2, CCL2, CD47, 
CLNS1A, CTSC, CTSD, CXCL10, CYB5R1, DAG1, 
DNAJA1, EBAG9, EIF4A1, FASTK, FOSB, FUT10, 
GDI1, GDI2, GNA11, GSTA4, GSTP1, GUCA2A, 
GUSB, H19, HLA-DMB, HLA-DRB1, HMGN2, 
HSPB8, KDM5C, LGALS9, LMAN2, MAL, 
MAP2K1, MT1E, MT2A, NACA, OTUB1,
PFDN1, PFDN5, PNN, PPP1CA, PPP1CB, 
PRKACA, RAB11A, RAB1A, RAB2A, RPL27A, 
RPS10, RPS15A, RPS24, SELK, SELT, SEPP1, 
SNRPB2, SNRPG, SOCS3, ST13, TES, TFF1, 
TIMP1, TIMP2, TMBIM6, TMEM47, TXNRD1, 
WFDC2, ZBED5
Pineal (Night) EXPRESSION 78 1.00E-16 ACTB, ANXA2, ANXA4, APP, APTX, ARG2, 
ARHGEF2, ATP1A1, ATP2A2, ATP6V0E1, 
BCL2L1, BCL2L2, BEX4, CA2, CCL2, CD47, 
CLNS1A, COL1A2, CTSC, CTSD, CXCL10, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FOSB, FUT10, GDI1, GDI2, GNA11, 
GSTA4, GSTP1, GUCA2A, GUSB, H19, HLA- 
DMB, HLA-DRB1, HMGN2, HSPB8, KDM5C, 
LGALS9, LMAN2, MAL, MAP2K1, MT1E,
MT2A, NACA, OTUB1, PFDN1, PFDN5, PNN, 
PPP1CA, PPP1CB, PRKACA, RAB11A, RAB1A, 
RAB2A, RPL27A, RPS10, RPS15A, RPS24, SELK, 
SELT, SEPP1, SNRPB2, SNRPG, SOCS3, ST13, 
TES, TFF1, TIMP1, TIMP2, TMBIM6, TMEM47, 
TXNRD1, ZBED5
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Bronchial
Epithelium
EXPRESSION 77 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BEX4, 
CCL2, CCL20, CD47, CLNS1A, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, DSG3, EBAG9, 
EIF4A1, FASTK, FUT10, FZD6, GDI1, GDI2, 
GNA11, GSTA4, GSTP1, GUCA2A, GUSB, H19, 
HLA-DMB, HLA-DRB1, HMGN2, HSPB8, 
KDM5C, KRT14, KRT19, LAMC2, LGALS9, 
LMAN2, MAL, MAP2K1, MT1E, MT2A, NACA, 
OTUB1, PFDN1, PFDN5, PLAU, PNN, PPP1CA, 
PPP1CB, PRKACA, RAB11A, RAB1A, RAB2A, 
RPL27A, RPS10, RPS15A, RPS24, SELK, SELT, 
SNRPB2, SNRPG, SOCS3, ST13, TBPL1, TES, 
TFF1, TIMP1, TIMP2, TMBIM6, TXNRD1, 
ZBED5
Endothelial EXPRESSION 76 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, ATP7B, BCL2L1, 
BEX4, BRCA1, CCL2, CD47, CLNS1A, CPNE1, 
CTSC, CTSD, CYB5R1, DAG1, DNAJA1, EBAG9, 
EIF4A1, FASTK, FOSB, FUT10, GDI1, GDI2, 
GNA11, GSTP1, GUCA2A, GUSB, H19, HLA- 
DMA, HLA-DMB, HLA-DRB1, HMGN2, HSPB8, 
KDM5C, LGALS9, LMAN2, MAL, MAP2K1, 
MAPK14, MT2A, NACA, OTUB1, PFDN1, 
PFDN5, PNN, POLDIP2, PPP1CA, PPP1CB, 
PRKACA, PRKDC, RAB11A, RAB1A, RAB2A, 
RPL27A, RPS10, RPS15A, RPS24, SELK, SELT, 
SEPP1, SNRPB2, SNRPG, SOCS3, ST13, TBPL1, 
TES, TFF1, TIMP1, TMBIM6, TXNRD1, ZBED5
mortality/aging PHENOTYPE 76 1.00E-16 ABCB1, ACTB, ADRA1B, APP, ATP1A1, 
ATP2A2, ATP7B, AVPR2, BCL2L1, BIRC3, 
BRCA1, CA2, CASP3, CCL2, CD47, CD97, CLN3, 
CLNS1A, COL1A2, CSF2, CTSD, CXCL10, DAG1, 
DSG3, EDN1, EFNB2, ERBB2, F2RL1, FLCN, 
FZD6, GNA11, GUCY1B3, GUSB, H19, HLA- 
DMA, HLA-DQB1, HMGN2, HSPB8, KRT14, 
KRT19, LAMC2, LIFR, MAP2K1, MAPK14, 
MCPH1, MGMT, MMP9, MSX2, MT2A, NACA, 
PDPN, PFDN1, PFDN5, PLAU, PNN, PODXL, 
POFUT1, PPP1CB, PRKACA, PRKCD, PRKDC, 
PTGER2, RHBDF2, RPL27A, SELK, SEPP1, 
SLC35C1, SNAI2, SOCS3, TBX2, TCOF1, TGFB1, 
TIMP1, TXNRD1, UTRN, ZFPM2
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Bone Marrow EXPRESSION 75 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BEX4, 
CCL2, CD47, CD97, CLNS1A, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FUT10, GDI1, GDI2, GNA11, GSTA4, 
GSTP1, GUCA2A, GUSB, H19, HLA-DMA, HLA- 
DMB, HLA-DRB1, HMGN2, HSPB8, KDM5C, 
LGALS9, LMAN2, MAL, MAP2K1, MAPK14, 
MMP9, MT1E, MT2A, NACA, OTUB1, PFDN1, 
PFDN5, PNN, PPP1CA, PPP1CB, PRKACA, 
PRKCD, RAB11A, RAB1A, RAB2A, RPL27A, 
RPS10, RPS15A, RPS24, SELK, SELT, SEPP1, 
SNRPB2, SNRPG, SOCS3, ST13, TES, TFF1, 
TIMP1, TIMP2, TMBIM6, TXNRD1, ZBED5
Pancreas EXPRESSION 75 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BEX4, 
CCL2, CCL20, CD47, CLDN3, CLNS1A, COL1A2, 
CTSC, CTSD, CYB5R1, DAG1, DNAJA1, EBAG9, 
EFNB2, EIF4A1, FASTK, FUT10, GDI1, GDI2, 
GNA11, GSTA4, GSTP1, GUCA2A, GUSB, H19, 
HLA-DMB, HLA-DRB1, HMGN2, HSPB8, 
KDM5C, KRT19, LGALS9, LMAN2, MAL, 
MAP2K1, MT1E, MT2A, NACA, OTUB1, 
PFDN1, PFDN5, PNN, PPP1CA, PPP1CB, 
PRKACA, RAB11A, RAB1A, RAB2A, RPL27A, 
RPS10, RPS15A, RPS24, SELK, SELT, SEPP1, 
SNRPB2, SNRPG, SOCS3, ST13, TES, TFF1, 
TIMP1, TIMP2, TMBIM6, TXNRD1, ZBED5
Uterus EXPRESSION 75 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BEX4, 
CCL2, CD47, CD97, CLNS1A, COL1A2, CTSC, 
CTSD, CYB5R1, DAG1, DNAJA1, EBAG9, 
EIF4A1, FASTK, FUT10, GDI1, GDI2, GNA11, 
GSTA4, GSTP1, GUCA2A, GUSB, H19, HLA- 
DMB, HLA-DRB1, HMGN2, HSPB8, KDM5C, 
KRT19, LGALS9, LMAN2, MAL, MAP2K1, 
MT1E, MT2A, NACA, OTUB1, PDPN, PFDN1, 
PFDN5, PNN, PODXL, PPP1CA, PPP1CB, 
PRKACA, RAB11A, RAB1A, RAB2A, RPL27A, 
RPS10, RPS15A, RPS24, SELK, SELT, SEPP1, 
SNRPB2, SNRPG, SOCS3, ST13, TES, TFF1, 
TIMP1, TIMP2, TMBIM6, TXNRD1, ZBED5
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Fetal Brain EXPRESSION 75 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BCL2L2, 
BEX4, CCL2, CD47, CLNS1A, CPNE1, CTSC, 
CTSD, CXCL10, CYB5R1, DAG1, DNAJA1, 
EBAG9, EIF4A1, FASTK, FUT10, GDI1, GDI2, 
GNA11, GSTA4, GSTP1, GUCA2A, GUCY1B3, 
GUSB, H19, HLA-DMB, HLA-DRB1, HMGN2, 
HSPB8, KDM5C, LGALS9, LMAN2, MAL, 
MAP2K1, MT1E, MT2A, NACA, OTUB1,
PFDN1, PFDN5, PNN, PPP1CA, PPP1CB, 
PRKACA, RAB11A, RAB1A, RAB2A, RPL27A, 
RPS10, RPS15A, RPS24, SELK, SELT, SEPP1, 
SLC1A1, SNRPB2, SNRPG, SOCS3, ST13, TES, 
TFF1, TIMP1, TIMP2, TMBIM6, TXNRD1, 
ZBED5
Amygdala EXPRESSION 75 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BCL2L2, 
BEX4, CA2, CCL2, CD47, CLNS1A, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FUT10, GDI1, GDI2, GNA11, GSTA4, 
GSTP1, GUCA2A, GUCY1B3, GUSB, H19, HLA- 
DMB, HLA-DRB1, HMGN2, HSPB8, KDM5C, 
LGALS9, LMAN2, MAL, MAP2K1, MT1E,
MT2A, NACA, OTUB1, PFDN1, PFDN5, PNN, 
PPP1CA, PPP1CB, PRKACA, RAB11A, RAB1A, 
RAB2A, RPL27A, RPS10, RPS15A, RPS24, SELK, 
SELT, SEPP1, SLC1A1, SNRPB2, SNRPG, SOCS3, 
ST13, TES, TFF1, TIMP1, TIMP2, TMBIM6, 
TMEM47, TXNRD1, ZBED5
Sup Cervical 
Ganglion
EXPRESSION 75 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BEX4, 
CCL17, CCL2, CD47, CLNS1A, COL1A2, CTSC, 
CTSD, CYB5R1, DAG1, DNAJA1, EBAG9, 
EIF4A1, FASTK, FUT10, GDI1, GDI2, GNA11, 
GSTA4, GSTP1, GUCA2A, GUSB, H19, HLA- 
DMB, HLA-DRB1, HMGN2, HSPB8, KDM5C, 
LGALS9, LIFR, LMAN2, MAL, MAP2K1, MSX2, 
MT1E, MT2A, NACA, OTUB1, PFDN1, PFDN5, 
PNN, PPP1CA, PPP1CB, PRKACA, RAB11A, 
RAB1A, RAB2A, RPL27A, RPS10, RPS15A, 
RPS24, SELK, SELT, SEPP1, SETMAR, SNRPB2, 
SNRPG, SOCS3, ST13, TES, TFF1, TIMP1, 
TIMP2, TMBIM6, TXNRD1, ZBED5
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Cardiac
Myocytes
EXPRESSION 75 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BEX4, 
CCL2, CD47, CLNS1A, COL1A2, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, EBAG9, EDN1, 
EIF4A1, FASTK, FUT10, FZD6, GDI1, GDI2, 
GNA11, GPX8, GSTA4, GSTP1, GUCA2A, 
GUSB, H19, HLA-DMB, HLA-DRB1, HMGN2, 
HSPB8, KDM5C, LGALS9, LMAN2, MAL, 
MAP2K1, MT1E, MT2A, NACA, OTUB1, 
PFDN1, PFDN5, PNN, PPP1CA, PPP1CB, 
PRKACA, RAB11A, RAB1A, RAB2A, RPL27A, 
RPS10, RPS15A, RPS24, SELK, SELT, SNAI2, 
SNRPB2, SNRPG, SOCS3, ST13, TBPL1, TES, 
TFF1, TIMP1, TIMP2, TMBIM6, TXNRD1, 
ZBED5
Fetal Thyroid EXPRESSION 75 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BEX4, 
CCL2, CD47, CLDN3, CLNS1A, COL1A2, CTSC, 
CTSD, CYB5R1, DAG1, DNAJA1, EBAG9,
EFNB2, EIF4A1, FASTK, FUT10, FZD6, GDI1, 
GDI2, GNA11, GSTA4, GSTP1, GUCA2A, GUSB, 
H19, HLA-DMB, HLA-DRB1, HMGN2, HSPB8, 
KDM5C, LGALS9, LMAN2, MAL, MAP2K1, 
MT1E, MT2A, NACA, OTUB1, PFDN1, PFDN5, 
PNN, PPP1CA, PPP1CB, PRKACA, RAB11A, 
RAB1A, RAB2A, RPL27A, RPS10, RPS15A, 
RPS24, SELK, SELT, SEPP1, SNRPB2, SNRPG, 
SOCS3, ST13, TES, TFF1, TIMP1, TIMP2, 
TMBIM6, TXNRD1, WFDC2, ZBED5
Pancreatic Islet EXPRESSION 75 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BEX4, 
CCL2, CCL20, CD47, CLNS1A, COL1A2, CTSC, 
CTSD, CYB5R1, DAG1, DNAJA1, EBAG9, 
EIF4A1, FASTK, FUT10, FXYD2, GDI1, GDI2, 
GNA11, GSTA4, GSTP1, GUCA2A, GUCY1B3, 
GUSB, H19, HLA-DMB, HLA-DRB1, HMGN2, 
HSPB8, KDM5C, KRT19, LGALS9, LMAN2, 
MAL, MAP2K1, MT1E, MT2A, NACA, OTUB1, 
PFDN1, PFDN5, PNN, PPP1CA, PPP1CB, 
PRKACA, RAB11A, RAB1A, RAB2A, RPL27A, 
RPS10, RPS15A, RPS24, SELK, SELT, SEPP1, 
SNRPB2, SNRPG, SOCS3, ST13, TES, TFF1, 
TIMP1, TIMP2, TMBIM6, TXNRD1, ZBED5
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Testis Germ EXPRESSION 75 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BEX4, 
CCL2, CD47, CLNS1A, COL1A2, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FUT10, GDI1, GDI2, GNA11, GSTA4, 
GSTP1, GUCA2A, GUSB, H19, HLA-DMB, HLA- 
DRB1, HMGN2, HSPB8, IL13RA2, KDM5C, 
LGALS9, LMAN2, MAL, MAP2K1, MT1E,
MT2A, NACA, OTUB1, PFDN1, PFDN5, PNN, 
PPP1CA, PPP1CB, PRKACA, RAB11A, RAB1A, 
RAB2A, RPL27A, RPS10, RPS15A, RPS24, SELK, 
SELT, SEPP1, SNRPB2, SNRPG, SOCS3, ST13, 
TBPL1, TES, TFF1, TIMP1, TIMP2, TMBIM6, 
TXNRD1, UTRN, WFDC2, ZBED5
Testis Intersitial EXPRESSION 75 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BEX4, 
CCL2, CD47, CLNS1A, COL1A2, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FUT10, GDI1, GDI2, GNA11, GSTA4, 
GSTP1, GUCA2A, GUSB, H19, HLA-DMB, HLA- 
DRB1, HMGN2, HSPB8, IL13RA2, KDM5C, 
LGALS9, LMAN2, MAL, MAP2K1, MT1E,
MT2A, NACA, OTUB1, PFDN1, PFDN5, PNN, 
PPP1CA, PPP1CB, PRKACA, RAB11A, RAB1A, 
RAB2A, RPL27A, RPS10, RPS15A, RPS24, SELK, 
SELT, SEPP1, SNRPB2, SNRPG, SOCS3, ST13, 
TBPL1, TES, TFF1, TIMP1, TIMP2, TMBIM6, 
TMEM57, TXNRD1, UTRN, ZBED5
Prefrontal
Cortex
EXPRESSION 74 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BCL2L2, 
BEX4, CA2, CCL2, CD47, CLNS1A, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FUT10, GDI1, GDI2, GNA11, GSTA4, 
GSTP1, GUCA2A, GUCY1B3, GUSB, H19, HLA- 
DMB, HLA-DRB1, HMGN2, HSPB8, KDM5C, 
LGALS9, LMAN2, MAL, MAP2K1, MT1E,
MT2A, NACA, OTUB1, PFDN1, PFDN5, PNN, 
PPP1CA, PPP1CB, PRKACA, RAB11A, RAB1A, 
RAB2A, RPL27A, RPS10, RPS15A, RPS24, SELK, 
SELT, SEPP1, SNRPB2, SNRPG, SOCS3, ST13, 
TES, TFF1, TIMP1, TIMP2, TMBIM6, TMEM47, 
TXNRD1, ZBED5
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Table A-2 continued
Descriptor Attribute type Score P Value Genes sharing this descriptor
Olfactory Bulb EXPRESSION 74 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BCL2L2, 
BEX4, CA2, CCL2, CD47, CLNS1A, COL1A2, 
CTSC, CTSD, CYB5R1, DAG1, DNAJA1, EBAG9, 
EIF4A1, FASTK, FUT10, GDI1, GDI2, GNA11, 
GSTA4, GSTP1, GUCA2A, GUSB, H19, HLA- 
DMB, HLA-DRB1, HMGN2, HSPB8, KDM5C, 
KRT14, LGALS9, LMAN2, MAL, MAP2K1,
MT1E, MT2A, NACA, OTUB1, PFDN1, PFDN5, 
PNN, PPP1CA, PPP1CB, PRKACA, RAB11A, 
RAB1A, RAB2A, RPL27A, RPS10, RPS15A, 
RPS24, SELK, SELT, SEPP1, SNRPB2, SNRPG, 
SOCS3, ST13, TES, TFF1, TIMP1, TIMP2, 
TMBIM6, TXNRD1, ZBED5
Hypothalamus EXPRESSION 74 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BCL2L2, 
BEX4, CA2, CCL2, CD47, CLNS1A, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FUT10, GDI1, GDI2, GNA11, GSTA4, 
GSTP1, GUCA2A, GUCY1B3, GUSB, H19, HLA- 
DMB, HLA-DRB1, HMGN2, HSPB8, KDM5C, 
LGALS9, LMAN2, MAL, MAP2K1, MT1E,
MT2A, NACA, OTUB1, PFDN1, PFDN5, PNN, 
PPP1CA, PPP1CB, PRKACA, RAB11A, RAB1A, 
RAB2A, RPL27A, RPS10, RPS15A, RPS24, SELK, 
SELT, SEPP1, SNRPB2, SNRPG, SOCS3, ST13, 
TES, TFF1, TIMP1, TIMP2, TMBIM6, TMEM47, 
TXNRD1, ZBED5
Fetal Liver EXPRESSION 74 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, ATP7B, BCL2L1, 
BEX4, CCL2, CD47, CLNS1A, COL1A2, CTSC, 
CTSD, CYB5R1, CYP4A11, DAG1, DNAJA1, 
EBAG9, EIF4A1, FASTK, FUT10, GDI1, GDI2, 
GNA11, GSTA4, GSTP1, GUCA2A, GUSB, H19, 
HLA-DMB, HLA-DRB1, HMGN2, HSPB8, 
KDM5C, LGALS9, LMAN2, MAL, MAP2K1, 
MT1E, MT2A, NACA, OTUB1, PFDN1, PFDN5, 
PNN, PPP1CA, PPP1CB, PRKACA, PRKDC, 
RAB11A, RAB1A, RAB2A, RPL27A, RPS10, 
RPS15A, RPS24, SELK, SELT, SEPP1, SNRPB2, 
SNRPG, SOCS3, ST13, TES, TFF1, TIMP1, 
TIMP2, TMBIM6, TXNRD1, ZBED5
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Table A-2 continued
Descriptor Attribute type Score P Value Genes sharing this descriptor
Trachea EXPRESSION 74 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BEX4, 
CCL2, CD47, CLNS1A, COL1A2, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FUT10, GDI1, GDI2, GNA11, GSTA4, 
GSTP1, GUCA2A, GUSB, H19, HLA-DMB, HLA- 
DRB1, HMGN2, HSPB8, KDM5C, KRT14, 
KRT19, LGALS9, LMAN2, MAL, MAP2K1, 
MT1E, MT2A, NACA, OTUB1, PFDN1, PFDN5, 
PNN, PPP1CA, PPP1CB, PRKACA, RAB11A, 
RAB1A, RAB2A, RPL27A, RPS10, RPS15A, 
RPS24, SELK, SELT, SEPP1, SNRPB2, SNRPG, 
SOCS3, ST13, TES, TFF1, TIMP1, TIMP2, 
TMBIM6, TXNRD1, WFDC2, ZBED5
Testis Seminif 
Tubule
EXPRESSION 74 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BEX4, 
CCL2, CD47, CLNS1A, COL1A2, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FUT10, GDI1, GDI2, GNA11, GSTA4, 
GSTP1, GUCA2A, GUSB, H19, HLA-DMB, HLA- 
DRB1, HMGN2, HSPB8, IL13RA2, KDM5C, 
LGALS9, LMAN2, MAL, MAP2K1, MT1E,
MT2A, NACA, OTUB1, PFDN1, PFDN5, PNN, 
PPP1CA, PPP1CB, PRKACA, RAB11A, RAB1A, 
RAB2A, RPL27A, RPS10, RPS15A, RPS24, SELK, 
SELT, SEPP1, SNRPB2, SNRPG, SOCS3, ST13, 
TBPL1, TES, TFF1, TIMP1, TIMP2, TMBIM6, 
TXNRD1, UTRN, ZBED5
Testis Leydig EXPRESSION 74 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BEX4, 
CCL2, CD47, CLNS1A, COL1A2, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FUT10, GDI1, GDI2, GNA11, GSTA4, 
GSTP1, GUCA2A, GUSB, H19, HLA-DMB, HLA- 
DRB1, HMGN2, HSPB8, IL13RA2, KDM5C, 
LGALS9, LMAN2, MAL, MAP2K1, MT1E,
MT2A, NACA, OTUB1, PFDN1, PFDN5, PNN, 
PPP1CA, PPP1CB, PRKACA, RAB11A, RAB1A, 
RAB2A, RPL27A, RPS10, RPS15A, RPS24, SELK, 
SELT, SEPP1, SNRPB2, SNRPG, SOCS3, ST13, 
TBPL1, TES, TFF1, TIMP1, TIMP2, TMBIM6, 
TXNRD1, UTRN, ZBED5
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Spinal Cord EXPRESSION 73 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BCL2L2, 
BEX4, CA2, CCL2, CD47, CLNS1A, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FUT10, GDI1, GDI2, GNA11, GSTA4, 
GSTP1, GUCA2A, GUSB, H19, HLA-DMB, HLA- 
DRB1, HMGN2, HSPB8, KDM5C, LGALS9, 
LMAN2, MAL, MAP2K1, MT1E, MT2A, NACA, 
OTUB1, PFDN1, PFDN5, PNN, PPP1CA, 
PPP1CB, PRKACA, RAB11A, RAB1A, RAB2A, 
RPL27A, RPS10, RPS15A, RPS24, SELK, SELT, 
SEPP1, SNRPB2, SNRPG, SOCS3, ST13, TES, 
TFF1, TIMP1, TIMP2, TMBIM6, TMEM47, 
TXNRD1, ZBED5
Cingulate Cortex EXPRESSION 73 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BCL2L2, 
BEX4, CA2, CCL2, CD47, CLNS1A, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FUT10, GDI1, GDI2, GNA11, GSTA4, 
GSTP1, GUCA2A, GUCY1B3, GUSB, H19, HLA- 
DMB, HLA-DRB1, HMGN2, HSPB8, KDM5C, 
LGALS9, LMAN2, MAL, MAP2K1, MT1E,
MT2A, NACA, OTUB1, PFDN1, PFDN5, PNN, 
PPP1CA, PPP1CB, PRKACA, RAB11A, RAB1A, 
RAB2A, RPL27A, RPS10, RPS15A, RPS24, SELK, 
SELT, SEPP1, SNRPB2, SNRPG, SOCS3, ST13, 
TES, TFF1, TIMP1, TIMP2, TMBIM6, TXNRD1, 
ZBED5
Parietal Lobe EXPRESSION 73 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BCL2L2, 
BEX4, CA2, CCL2, CD47, CLNS1A, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FUT10, GDI1, GDI2, GNA11, GSTA4, 
GSTP1, GUCA2A, GUCY1B3, GUSB, H19, HLA- 
DMB, HLA-DRB1, HMGN2, HSPB8, KDM5C, 
LGALS9, LMAN2, MAL, MAP2K1, MT1E,
MT2A, NACA, OTUB1, PFDN1, PFDN5, PNN, 
PPP1CA, PPP1CB, PRKACA, RAB11A, RAB1A, 
RAB2A, RPL27A, RPS10, RPS15A, RPS24, SELK, 
SELT, SEPP1, SNRPB2, SNRPG, SOCS3, ST13, 
TES, TFF1, TIMP1, TIMP2, TMBIM6, TXNRD1, 
ZBED5
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Temporal Lobe EXPRESSION 73 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BCL2L2, 
BEX4, CA2, CCL2, CD47, CLNS1A, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FUT10, GDI1, GDI2, GNA11, GSTA4, 
GSTP1, GUCA2A, GUCY1B3, GUSB, H19, HLA- 
DMB, HLA-DRB1, HMGN2, HSPB8, KDM5C, 
LGALS9, LMAN2, MAL, MAP2K1, MT1E,
MT2A, NACA, OTUB1, PFDN1, PFDN5, PNN, 
PPP1CA, PPP1CB, PRKACA, RAB11A, RAB1A, 
RAB2A, RPL27A, RPS10, RPS15A, RPS24, SELK, 
SELT, SEPP1, SNRPB2, SNRPG, SOCS3, ST13, 
TES, TFF1, TIMP1, TIMP2, TMBIM6, TXNRD1, 
ZBED5
Occipital Lobe EXPRESSION 73 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BCL2L2, 
BEX4, CA2, CCL2, CD47, CLNS1A, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FUT10, GDI1, GDI2, GNA11, GSTA4, 
GSTP1, GUCA2A, GUCY1B3, GUSB, H19, HLA- 
DMB, HLA-DRB1, HMGN2, HSPB8, KDM5C, 
LGALS9, LMAN2, MAL, MAP2K1, MT1E,
MT2A, NACA, OTUB1, PFDN1, PFDN5, PNN, 
PPP1CA, PPP1CB, PRKACA, RAB11A, RAB1A, 
RAB2A, RPL27A, RPS10, RPS15A, RPS24, SELK, 
SELT, SEPP1, SNRPB2, SNRPG, SOCS3, ST13, 
TES, TFF1, TIMP1, TIMP2, TMBIM6, TXNRD1, 
ZBED5
Cerebellum
Peduncles
EXPRESSION 73 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BCL2L2, 
BEX4, CA2, CCL2, CD47, CLNS1A, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FUT10, GDI1, GDI2, GNA11, GSTA4, 
GSTP1, GUCA2A, GUSB, H19, HLA-DMB, HLA- 
DRB1, HMGN2, HSPB8, KDM5C, LGALS9, 
LMAN2, MAL, MAP2K1, MT1E, MT2A, NACA, 
OTUB1, PFDN1, PFDN5, PNN, PPP1CA, 
PPP1CB, PRKACA, RAB11A, RAB1A, RAB2A, 
RPL27A, RPS10, RPS15A, RPS24, SELK, SELT, 
SEPP1, SNRPB2, SNRPG, SOCS3, ST13, TES, 
TFF1, TIMP1, TIMP2, TMBIM6, TXNRD1, 
ZBED5, ZFPM2
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Thalamus EXPRESSION 73 1.00E-16 ACTB, ANXA2, ANXA4, APP, ARHGEF2, 
ATP1A1, ATP2A2, ATP6V0E1, BCL2L1, BCL2L2, 
BEX4, CA2, CCL2, CD47, CLNS1A, CTSC, CTSD, 
CYB5R1, DAG1, DNAJA1, EBAG9, EIF4A1, 
FASTK, FUT10, GDI1, GDI2, GNA11, GSTA4, 
GSTP1, GUCA2A, GUCY1B3, GUSB, H19, HLA- 
DMB, HLA-DRB1, HMGN2, HSPB8, KDM5C, 
LGALS9, LMAN2, MAL, MAP2K1, MT1E,
MT2A, NACA, OTUB1, PFDN1, PFDN5, PNN, 
PPP1CA, PPP1CB, PRKACA, RAB11A, RAB1A, 
RAB2A, RPL27A, RPS10, RPS15A, RPS24, SELK, 
SELT, SEPP1, SNRPB2, SNRPG, SOCS3, ST13, 
TES, TFF1, TIMP1, TIMP2, TMBIM6, TXNRD1, 
ZBED5
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Appendix B 
IPA -  Networks
Table B-1: Gene networks identified by Ingenuity Pathway Analysis Software
Molecules in Network Score Focus
Molecules
Top Diseases and 
Functions
Akt, ANXA2, Ap1, ATP1A1, calpain, CCL2, CCL17, CD3, 
Cyclin D, ERK1/2, F2RL1, GDI1, GDI2, H19, HLA-DMB, 
HLA-DR, HLA-DRB1, Ifnar, Interferon alpha, Jnk, MUC1, 
P38 MAPK, PDGF BB, PDPN, PI3K(complex), Pkc(s), 
PSMB8, PSMB9, SLC1A1, SLC35B2, Sos, SRC (family), 
TCR, UTRN, Vegf
43 17 Cell-To-Cell Signaling 
and Interaction, 
Hematological 
System Development 
and Function, Cell- 
mediated Immune 
Response
ANXA4, APP, ATP2A2, BCAR3, BSG, CD300LD, CHTOP, 
CLNS1A, DDX54, EIF4EBP3, ERK, ERRFI1, ESRRA, FSH, 
GALK1, GGCT, GSK3B, Ins1, KSR1, LMO4, MAP3K4, 
Mlcp, NFkB (complex), OTUB1, PLAT, PPP1CB, 
PPP1R13L, RNA polymerase II, RPS14, RPS25, SMYD3, 
TFF1, TFIIA, TMBIM6, TNFRSF10B
22 10 Cell Death and 
Survival, Cellular 
Compromise, 
Neurological Disease
AHNAK, ATP1B3, BCS1L, CACNA1C, CGN, CTSB, 
CYP4A11, DLC1, DNAJA1, EIF4A1, EIF4H, KIAA1524, 
LPPR4, MED14, MED23, MGMT, MID1, MLH1, NR2C2, 
OTUD6B, PAIP1, PPAR ligand-PPAR-Retinoic acid-RXRa, 
PPME1, PTGES, RPL4, RPL7, RPL10, RPS14, RPS19, 
S100A10, TNFRSF10B, tretinoin, UBASH3B, UBC, UBE3A
7 4 Cancer, 
Hematological 
Disease, Lipid 
Metabolism
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